1. Sarnak MJ, Levey AS: "Epidemiology of Cardiac Disease" in Dialysis Patients: Uremia-Related Risk Factors. Seminars in Dialysis 12:69-76, 1999
2. U.S. Renal Data System: USRDS 2002 Annual Data Report, in, Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive Diseases, 2002
3. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725-1730, 1999
4. Bonal J, Cleries M, Vela E: Transplantation versus haemodialysis in elderly patients. Renal Registry Committee. Nephrol Dial Transplant 12:261-264, 1997
5. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697-701, 1974
6. Rostand SG, Gretes JC, Kirk KA, Rutsky EA, Andreoli TE: Ischemic heart disease in patients with uremia undergoing maintenance hemodialysis. Kidney Int 16:600-611, 1979
7. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 339:799-805, 1998
8. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, Garg M, McCullough PA: Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis 37:1191-1200, 2001
9. Ansari A, Kaupke CJ, Vaziri ND, Miller R, Barbari A: Cardiac pathology in patients with end-stage renal disease maintained on hemodialysis. Int J Artif Organs 16:31-36, 1993
10. Hida M, Saitoh H, Satoh T: Autopsy findings in diabetic nephropathy patients under dialysis, collected from the annuals of pathological autopsy cases in Japan. Tokai J Exp Clin Med 9:357-362, 1984
11. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15:218-223, 2000
12. Clyne N, Lins LE, Pehrsson SK: Occurrence and significance of heart disease in uraemia. An autopsy study. Scand J Urol Nephrol 20:307-311, 1986
13. Bleyer AJ, Russell GB, Satko SG: Sudden and cardiac death rates in hemodialysis patients. Kidney Int 55:1553-1559, 1999
14. Parekh RS, Carroll CE, Wolfe RA, Port FK: Cardiovascular mortality in children and young adults with end-stage kidney disease. J Pediatr 141:191-197, 2002
15. Chavers BM, Li S, Collins AJ, Herzog CA: Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 62:648-653, 2002
16. Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, Wolff ED, Davin JC, Heymans HS: Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int 61:621-629, 2002
17. U.S. Renal Data System: USRDS 2003 Annual Data Report, in, Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive Diseases, 2003
18. Anderson RN, Smith BL: Deaths: leading causes for 2001. Natl Vital Stat Rep 52:1-85, 2003
19. Neu AM, Ho PL, McDonald RA, Warady BA: Chronic dialysis in children and adolescents. The 2001 NAPRTCS Annual Report. Pediatr Nephrol 17:656-663, 2002
20. Honda M: The 1997 Report of the Japanese National Registry data on pediatric peritoneal dialysis patients. Perit Dial Int 19:S473-478, 1999 (suppl 2)
21. Verrina E, Perfumo F, Calevo MG, Rinaldi S, Sorino P, Andreetta B, Bonaudo R, Lavoratti G, Edefonti A: The Italian Pediatric Chronic Peritoneal Dialysis Registry. Perit Dial Int 19:S479-483, 1999 (suppl 2)
22. Reiss U, Wingen AM, Scharer K: Mortality trends in pediatric patients with chronic renal failure. Pediatr Nephrol 10:41-45, 1996
23. Hisano S, Tsuru N, Itoh Y, Hattori S, Uchiyama M, Tamanaha K, Ninomiya M, Furuse A, Yamagishi M, Hohjoh M, et al.: Epidemiologic survey of children with end-stage renal disease. Acta Paediatr Jpn 32:343-348, 1990
24. Ehrich JH, Rizzoni G, Brunner FP, Fassbinder W, Geerlings W, Mallick NP, Raine AE, Selwood NH, Tufveson G: Renal replacement therapy for end-stage renal failure before 2 years of age. Nephrol Dial Transplant 7:1171-1177, 1992
25. Bosch A, Ulmer HE, Keller HE, Bonzel KE, Scharer K: Electrocardiographic monitoring in children with chronic renal failure. Pediatr Nephrol 4:140-144, 1990
26. Butani L, Berg G, Makker SP: QTc interval in children with chronic renal failure and with renal transplants. Pediatr Nephrol 17:6-9, 2002
27. Kocak G, Atalay S, Bakkaloglu S, Ekim M, Tutar HE, Imamoglu A: QT/corrected QT (QTc) intervals and QT/QTc dispersions in children with chronic renal failure. Int J Cardiol 70:63-67, 1999
28. Valsangiacomo E, Neuhaus TJ, Goetschel P, Bauersfeld U: Cardiac rhythm disturbances in children on hemodialysis. Pediatr Nephrol 17:837-841, 2002
29. Nayir A, Bilge I, Kilicaslan I, Ander H, Emre S, Sirin A: Arterial changes in paediatric haemodialysis patients undergoing renal transplantation. Nephrol Dial Transplant 16:2041-2047, 2001
30. Pennisi AJ, Heuser ET, Mickey MR, Lipsey A, Malekzadeh MH, Fine RN: Hyperlipidemia in pediatric hemodialysis and renal transplant patients. Associated with coronary artery disease. Am J Dis Child 130:957-961, 1976
31. Eifinger F, Wahn F, Querfeld U, Pollok M, Gevargez A, Kriener P, Gronemeyer D: Coronary artery calcifications in children and young adults treated with renal replacement therapy. Nephrol Dial Transplant 15:1892-1894, 2000
32. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
33. Milliner DS, Zinsmeister AR, Lieberman E, Landing B: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931-936, 1990
34. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100-105, 2002
35. Gruppen MP, Groothoff JW, Prins M, van der Wouw P, Offringa M, Bos WJ, Davin JC, Heymans HS: Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int 63:1058-1065, 2003
36. Litwin M, Grenda R, Prokurat S, Abuauba M, Latoszynska J, Jobs K, Boguszewska-Baczkowska A, Wawer ZT: Patient survival and causes of death on hemodialysis and peritoneal dialysis–single-center study. Pediatr Nephrol 16:996-1001, 2001
37. Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, Daniels SR: Left ventricular mass and systolic performance in pediatric patients with chronic renal failure. Circulation 107:864-868, 2003
38. NAPRTCS Annual Report 2001, in, Boston, MA, North American Pediatric Renal Transplant Cooperative Study Administrative Office, 2001, pp Part 3: Sec. 8-13
39. Aksu N, Yavascan O, Erdogan H, Dorak MC, Kansoy S, Kozan M: Echocardiographic evaluation in children treated with CAPD. Adv Perit Dial 14:255-257, 1998
40. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF: Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 14:898-902, 2000
41. Atalay S, Ekim M, Tutar HE, Kocak G, Bakkaloglu S, Tumer N: Systolic and diastolic function in children with chronic renal failure. Pediatr Int 44:18-23, 2002
42. Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF: Changes in left ventricular mass in children and adolescents during chronic dialysis. Pediatr Nephrol 16:318-323, 2001
43. Rivenes SM, Colan SD, Easley KA, Kaplan S, Jenkins KJ, Khan MN, Lai WW, Lipshultz SE, Moodie DS, Starc TJ, Sopko G, Zhang W, Bricker JT: Usefulness of the pediatric electrocardiogram in detecting left ventricular hypertrophy: results from the Prospective Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) multicenter study. Am Heart J 145:716-723, 2003
44. Fogel MA, Lieb DR, Seliem MA: Validity of electrocardiographic criteria for left ventricular hypertrophy in children with pressure- or volume-loaded ventricles: comparison with echocardiographic left ventricular muscle mass. Pediatr Cardiol 16:261-269, 1995
45. Bonow RO, Carabello B, de Leon AC, Edmunds LH, Jr., Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O’Gara PT, O’Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A, Jr., Gibbons RJ, Russell RO, Ryan TJ, Smith SC, Jr.: ACC/AHA Guidelines for the Management of Patients With Valvular Heart Disease. Executive Summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). J Heart Valve Dis 7:672-707, 1998
46. Cecchin F, Jorgenson DB, Berul CI, Perry JC, Zimmerman AA, Duncan BW, Lupinetti FM, Snyder D, Lyster td, Rosenthal GL, Cross B, Atkins DL: Is arrhythmia detection by automatic external defibrillator accurate for children? sensitivity and specificity of an automatic external defibrillator algorithm in 696 pediatric arrhythmias. Circulation 103:2483-2488, 2001
47. Atkins DL, Hartley LL, York DK: Accurate recognition and effective treatment of ventricular fibrillation by automated external defibrillators in adolescents. Pediatrics 101:393-397, 1998
48. Samson R, Berg R, Bingham R: Use of automated external defibrillators for children: an update. An advisory statement from the Pediatric Advanced Life Support Task Force, International Liaison Committee on Resuscitation. Resuscitation 57:237-243, 2003
49. Standards of medical care in diabetes. Diabetes Care 27 Suppl 1:S15-35, 2004
50. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555-576, 2004
51. KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 41:S1-S92, 2003 (suppl 3)
52. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30:S192-240, 1997 (suppl 3)
53. Gaston RS, Danovitch GM, Adams PL, Wynn JJ, Merion RM, Deierhoi MH, Metzger RA, Cecka JM, Harmon WE, Leichtman AB, Spital A, Blumberg E, Herzog CA, Wolfe RA, Tyan DB, Roberts J, Rohrer R, Port FK, Delmonico FL: The report of a national conference on the wait list for kidney transplantation. Am J Transplant 3:775-785, 2003
54. U.S. Renal Data System: USRDS 2001 Annual Data Report, in, Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive Diseases, 2001
55. Herzog CA: How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 14:2556-2572, 2003
56. Herzog CA, Marwick TH, Pheley AM, White CW, Rao VK, Dick CD: Dobutamine stress echocardiography for the detection of significant coronary artery disease in renal transplant candidates. Am J Kidney Dis 33:1080-1090, 1999
57. Dahan M, Viron BM, Faraggi M, Himbert DL, Lagallicier BJ, Kolta AM, Pessione F, Le Guludec D, Gourgon R, Mignon FE: Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int 54:255-262, 1998
58. Rabbat CG, Treleaven DJ, Russell JD, Ludwin D, Cook DJ: Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol 14:431-439, 2003
59. Wright RS, Reeder GS, Herzog CA, Albright RC, Williams BA, Dvorak DL, Miller WL, Murphy JG, Kopecky SL, Jaffe AS: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 137:563-570, 2002
60. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 137:555-562, 2002
61. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ: Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144:226-232, 2002
62. Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, Lincoff AM, Topol EJ, Ellis SG: Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol 89:1209-1211, 2002
63. Best PJ, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, Herzog CA, Holmes DR, Jr., Berger PB: Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 146:345-350, 2003
64. Frilling B, Zahn R, Fraiture B, Mark B, Donges K, Becker T, Siegler KE, Seidl K, Rustige J, Senges J: Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. Am J Cardiol 89:450-452, 2002
65. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA: Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 41:718-724, 2003
66. Kaufman JS, O’Connor TZ, Zhang JH, Cronin RE, Fiore LD, Ganz MB, Goldfarb DS, Peduzzi PN: Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14:2313-2321, 2003
67. Herzog CA, Ma JZ, Collins AJ: Comparative Survival of Dialysis Patients in the United States After Coronary Angioplasty, Coronary Artery Stenting, and Coronary Artery Bypass Surgery and Impact of Diabetes. Circulation 106:2207-2211, 2002
68. Herzog CA, Ma JZ, Collins AJ: Long-term outcome of dialysis patients in the United States with coronary revascularization procedures. Kidney Int 56:324-332, 1999
69. Szczech LA, Reddan DN, Owen WF, Califf R, Racz M, Jones RH, Hannan EL: Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 60:292-299, 2001
70. Herzog CA, Ma JZ, Collins AJ: Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation 105:1336-1341, 2002
71. Azar RR, Prpic R, Ho KK, Kiernan FJ, Shubrooks SJ, Jr., Baim DS, Popma JJ, Kuntz RE, Cohen DJ: Impact of end-stage renal disease on clinical and angiographic outcomes after coronary stenting. Am J Cardiol 86:485-489, 2000
72. Hase H, Nakamura M, Joki N, Tsunoda T, Nakamura R, Saijyo T, Morishita M, Yamaguchi T: Independent predictors of restenosis after percutaneous coronary revascularization in haemodialysis patients. Nephrol Dial Transplant 16:2372-2377, 2001
73. Rinehart AL, Herzog CA, Collins AJ, Flack JM, Ma JZ, Opsahl JA: A comparison of coronary angioplasty and coronary artery bypass grafting outcomes in chronic dialysis patients. Am J Kidney Dis 25:281-290, 1995
74. Agirbasli M, Weintraub WS, Chang GL, King SB, Guyton RA, Thompson td, Alameddine F, Ghazzal ZM: Outcome of coronary revascularization in patients on renal dialysis. Am J Cardiol 86:395-399, 2000
75. Koyanagi T, Nishida H, Kitamura M, Endo M, Koyanagi H, Kawaguchi M, Magosaki N, Sumiyoshi T, Hosoda S: Comparison of clinical outcomes of coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in renal dialysis patients. Ann Thorac Surg 61:1793-1796, 1996
76. London GM, Pannier B, Marchais SJ, Guerin AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 11:778-783, 2000
77. Urena P, Malergue MC, Goldfarb B: Evolutive aortic stenosis in HD patients: Analysis of risk factors. Nephrologie 20: 217-225, 1999
78. KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 42:S1-S202, 2003 (suppl 3)
79. Wongpraparut N, Apiyasawat S, Crespo G, Yazdani K, Jacobs LE, Kotler MN: Determinants of progression of aortic stenosis in patients aged > or =40 years. Am J Cardiol 89:350-352, 2002
80. Palta S, Pai AM, Gill KS, Pai RG: New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101:2497-2502, 2000
81. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
82. Kaplon RJ, Cosgrove DM, Gillinov AM, Lytle BW, Blackstone EH, Smedira NG: Cardiac valve replacement in patients on dialysis: influence of prosthesis on survival. Ann Thoracic Surg 70:438-441, 2000
83. Lucke JC, Samy RN, Atkins BZ, Silvestry SC, Douglas JM, Schwab SJ, Wolfe WG, Glower DD: Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients. Ann Thoracic Surg 64:129-132, 1997
84. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
85. Harnett JD, Foley RN, Kent GM, Barre PE, Murray D, Parfrey PS: Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995
86. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE: Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 49:1428-1434, 1996
87. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12:2768-2774, 2001
88. De Lima J, Vieira M, Abensur H, Krieger E: Baseline blood pressure and other variables influencing survival on haemodialysis of patients without overt cardiovascular disease. Nephrol Dial Transplant 16:793-797, 2001
89. Cice G, Ferrara L, Di Benedetto A, Russo PE, Marinelli G, Pavese F, Iacono A: Dilated cardiomyopathy in dialysis patients–beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J Am Coll Cardiol 37:407-411, 2001
90. Cice G, Ferrara L, D’Andrea A, D’Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438-1444, 2003
91. Robson R, Collins J, Johnson R, Kitching R, Searle M, Walker R, Douglas J, Leary J, Whalley G, Sharpe N, MacMahon S: Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis. The Perfect Study Collaborative Group. J Nephrol 10:33-40, 1997
92. Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM: Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 32:570-574, 1998
93. Herzog CA: Cardiac arrest in dialysis patients: approaches to alter an abysmal outcome. Kidney Int Suppl 84:S197-200, 2003
94. D’Elia JA, Weinrauch LA, Gleason RE, Hampton LA, Smith-Ossman S, Yoburn DC, Kaldany A, Healy RW, Leland OS, Jr.: Application of the ambulatory 24-hour electrocardiogram in the prediction of cardiac death in dialysis patients. Arch Intern Med 148:2381-2385, 1988
95. Karnik JA, Young BS, Lew NL, Herget M, Dubinsky C, Lazarus JM, Chertow GM: Cardiac arrest and sudden death in dialysis units. Kidney Int 60:350-357, 2001
96. Morrison G, Michelson EL, Brown S, Morganroth J: Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients. Kidney Int 17:811-819, 1980
97. Munger MA, Ateshkadi A, Cheung AK, Flaharty KK, Stoddard GJ, Marshall EH: Cardiopulmonary events during hemodialysis: effects of dialysis membranes and dialysate buffers. Am J Kidney Dis 36:130-139, 2000
98. Stevens LA, Levin A: Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002. Curr Opin Nephrol Hypertens 12:133-138, 2003
99. Levin A: Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int Suppl 80:35-38, 2002
100. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125-134, 1999
101. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS: Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65:1492-1498, 2004
102. Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemodialysed patients. Gruppo Emodialisi e Patologie Cardiovasculari. Lancet 2:305-309, 1988
103. Erem C, Kulan K, Tuncer C, Bostan M, Mocan Z, Komsuoglu B: Cardiac arrhythmias in patients on maintenance hemodialysis. Acta Cardiol 52:25-36, 1997
104. Meier P, Vogt P, Blanc E: Ventricular arrhythmias and sudden cardiac death in end-stage renal disease patients on chronic hemodialysis. Nephron 87:199-214, 2001
105. Narula AS, Jha V, Bali HK, Sakhuja V, Sapru RP: Cardiac arrhythmias and silent myocardial ischemia during hemodialysis. Ren Fail 22:355-368, 2000
106. Ansari N, Manis T, Feinfeld DA: Symptomatic atrial arrhythmias in hemodialysis patients. Ren Fail 23:71-76, 2001
107. Renke M, Zegrzda D, Liberek T, Dudziak M, Lichodziejewska-Niemierko M, Kubasik A, Rutkowski B: Interrelationship between cardiac structure and function and incidence of arrhythmia in peritoneal dialysis patients. Int J Artif Organs 24:374-379, 2001
108. Collins AJ, Li S, Ma JZ, Herzog C: Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 38:S26-29, 2001 (suppl 1)
109. Coresh J, Longenecker JC, Miller ER, Young 3rd, HJ, Klag MJ: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 9:S24-30, 1998
110. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16-23, 1998
111. Foley RN, Parfrey PS, Harnett JD, Kent GM, Hu L, O’Dea R, Murray DC, Barre PE: Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 16:386-393, 1996
112. Saran R, Bragg-Gresham JL, Rayner HC, Goodkin DA, Keen ML, Van Dijk PC, Kurokawa K, Piera L, Saito A, Fukuhara S, Young EW, Held PJ, Port FK: Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64:254-262, 2003
113. Goodkin DA, Mapes DL, Held PJ: The dialysis outcomes and practice patterns study (DOPPS): how can we improve the care of hemodialysis patients? Semin Dial 14:157-159, 2001
114. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14:3270-3277, 2003
115. Hecking E, Bragg-Gresham JL, Rayner HC, Pisoni RL, Andreucci VE, Combe C, Greenwood R, McCullough K, Feldman HI, Young EW, Held PJ, Port FK: Haemodialysis prescription, adherence and nutritional indicators in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19:100-107, 2004
116. Abbott KC, Trespalacios FC, Taylor AJ, Agodoa LY: Atrial fibrillation in chronic dialysis patients in the United States: risk factors for hospitalization and mortality. BMC Nephrol 4:1, 2003
117. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877-883, 2002
118. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G: A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341:1882-1890, 1999
119. Buxton AE: The clinical use of implantable cardioverter defibrillators: where are we now? Where should we go? Ann Intern Med 138:512-514, 2003
120. Cairns JA, Connolly SJ, Roberts R, Gent M: Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 349:675-682, 1997
121. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350:2151-2158, 2004
122. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM: Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140-2150, 2004
123. Josephson ME, Callans DJ, Buxton AE: The role of the implantable cardioverter-defibrillator for prevention of sudden cardiac death. Ann Intern Med 133:901-910, 2000
124. Kennedy HL: Beta blockade, ventricular arrhythmias, and sudden cardiac death. Am J Cardiol 80:29J-34J, 1997
125. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 337:1576-1583, 1997
126. Bocker D, Block M, Isbruch F, Fastenrath C, Castrucci M, Hammel D, Scheld HH, Borggrefe M, Breithardt G: Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J 73:158-163, 1995
127. Janse MJ: A brief history of sudden cardiac death and its therapy. Pharmacol Ther 100:89-99, 2003
128. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, Torp-Pedersen C, Scherhag A, Skene A: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7-13, 2003
129. Christensen JH, Gustenhoff P, Korup E, Aaroe J, Toft E, Moller J, Rasmussen K, Dyerberg J, Schmidt EB: Effect of fish oil on heart rate variability in survivors of myocardial infarction: a double blind randomised controlled trial. Brit Med J 312:677-678, 1996
130. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784-1790, 2002
131. Zuanetti G, Maggioni AP, Keane W, Ritz E: Nephrologists neglect administration of betablockers to dialysed diabetic patients. Nephrol Dial Transplant 12:2497-2500, 1997
132. Huynh-Do U, Wahl C, Sulzer M, Buhler H, Keusch G: Torsades de pointes during low-dosage sotalol therapy in haemodialysis patients. Nephrol Dial Transplant 11:1153-1154, 1996
133. Rizza C, Valderrabano M, Singh BN: Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease. J Cardiovasc Pharmacol Ther 4:129-134, 1999
134. Donnan GA, Dewey HM, Chambers BR: Warfarin for atrial fibrillation: the end of an era? Lancet Neurol 3:305-308, 2004
135. Halperin JL: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146:431-438, 2003
136. Olsson SB: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362:1691-1698, 2003
137. Becker L, Eisenberg M, Fahrenbruch C, Cobb L: Cardiac arrest in medical and dental practices: implications for automated external defibrillators. Arch Intern Med 161:1509-1512, 2001
138. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10: pediatric advanced life support. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 102:I291-342, 2000
139. Seliger SL, Gillen DL, Longstreth WTJ, Kestenbaum B, Stehman-Breen CO: Elevated risk of stroke among patients with end-stage renal disease. Kidney Int 64:603-609, 2003
140. Kawamura M, Fijimoto S, Hisanaga S, Yamamoto Y, Eto T: Incidence, outcome, and risk factors of cerebrovascular events in patients undergoing maintenance hemodialysis. Am J Kidney Dis 31:991-996, 1998
141. Iseki K, Fukiyama K: Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int 50:1672-1675, 1996
142. Pascazio L, Bianco F, Giorgini A, Galli G, Curri G, Panzetta G: Echo color Doppler imaging of carotid vessels in hemodialysis patients: evidence of high levels of atherosclerotic lesions. Am J Kidney Dis 28:713-720, 1996
143. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C: Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 12:2458-2464, 2001
144. Eggers PW, Gohdes D, Pugh J: Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. Kidney Int 56:1524-1533, 1999
145. O’Hare AM, Bacchetti P, Segal M, Hsu CY, Johansen KL: Factors associated with future amputation among patients undergoing hemodialysis: results from the Dialysis Morbidity and Mortality Study Waves 3 and 4. Am J Kidney Dis 41:162-170, 2003
146. Leskinen Y, Salenius JP, Lehtimaki T, Huhtala H, Saha H: The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 40:472-479, 2002
147. Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK: Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis 27:668-672, 1996
148. Ono K, Tsuchida A, Kawai H, Matsuo H, Wakamatsu R, Maezawa A, Yano S, Kawada T, Nojima Y: Ankle-brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol 14:1591-1598, 2003
149. Hiatt WR: Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344:1608-1621, 2001
150. Reddan DN, Marcus RJ, Owen WF, Jr., Szczech LA, Landwehr DM: Long-term outcomes of revascularization for peripheral vascular disease in end-stage renal disease patients. Am J Kidney Dis 38:57-63, 2001
151. Dossa CD, Shepard AD, Amos AM, Kupin WL, Reddy DJ, Elliott JP, Wilczwski JM, Ernst CB: Results of lower extremity amputations in patients with end-stage renal disease. J Vasc Surg 20:14-19, 1994
152. Korn P, Hoenig SJ, Skillman JJ, Kent KC: Is lower extremity revascularization worthwhile in patients with end-stage renal disease? Surgery 128:472-479, 2000
153. Johnson BL, Glickman MH, Bandyk DF, Esses GE: Failure of foot salvage in patients with end-stage renal disease after surgical revascularization. J Vasc Surg 22:280-285; discussion 285-286, 1995
154. O’Hare AM, Feinglass J, Sidawy AN, Bacchetti P, Rodriguez RA, Daley J, Khuri S, Henderson WG, Johansen KL: Impact of renal insufficiency on short-term morbidity and mortality after lower extremity revascularization: data from the Department of Veterans Affairs’ National Surgical Quality Improvement Program. J Am Soc Nephrol 14:1287-1295, 2003
155. Sakurai T, Kobayashi M, Harasawa H, Itoh A, Yamazaki C, Masuko K: Infrainguinal arterial reconstruction in end-stage renal disease. Cardiovasc Surg 3:46-49, 1995
156. Lumsden AB, Besman A, Jaffe M, MacDonald MJ, Allen RC: Infrainguinal revascularization in end-stage renal disease. Ann Vasc Surg 8:107-112, 1994
157. Simsir SA, Cabellon A, Kohlman-Trigoboff D, Smith BM: Factors influencing limb salvage and survival after amputation and revascularization in patients with end-stage renal disease. Am J Surg 170:113-117, 1995
158. Baele HR, Piotrowski JJ, Yuhas J, Anderson C, Alexander JJ: Infrainguinal bypass in patients with end-stage renal disease. Surgery 117:319-324, 1995
159. Oishi K, Nagake Y, Yamasaki H, Fukuda S, Ichikawa H, Ota K, Makino H: The significance of atherogenic indices in patients on hemodialysis. Am J Nephrol 20:107-115, 2000
160. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 26:S51-61, 2003 (suppl 1)
161. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
162. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381-389, 2000
163. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998
164. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865, 1998
165. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39:297-307, 2002
166. Oyibo SO, Pritchard GM, McLay L, James E, Laing I, Gokal R, Boulton AJ: Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Diabet Med 19:693-696, 2002
167. Tzamaloukas AH: Interpreting glycosylated hemoglobin in diabetic patients on peritoneal dialysis. Adv Perit Dial 12:171-175, 1996
168. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 25:148-198, 2002
169. Clinical practice guidelines for nutrition in chronic renal failure. KDOQI, National Kidney Foundation. Am J Kidney Dis 35:S1-140, 2000 (suppl 2)
170. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206-1252, 2003
171. Lameire N, Van Biesen W: Importance of blood pressure and volume control in peritoneal dialysis patients. Perit Dial Int 21:206-211, 2001
172. Medcalf JF, Harris KP, Walls J: Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int 59:1128-1133, 2001
173. Stegmayr BG: Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients. Perit Dial Int 17:541-545, 1997
174. Stegmayr BG: Beta-blocker use in peritoneal dialysis patients. Semin Dial 14:73, 2001
175. Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 115:291-297, 2003
176. Ritz E, Koch M: Morbidity and mortality due to hypertension in patients with renal failure. Am J Kidney Dis 21:113-118, 1993
177. Foley RN, Parfrey PS: Cardiovascular disease and mortality in ESRD. J Nephrol 11:239-245, 1998
178. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 54:561-569, 1998
179. Duranti E, Imperiali P, Sasdelli M: Is hypertension a mortality risk factor in dialysis? Kidney Int Suppl 55:S173-174, 1996
180. U.S. Renal Data System: USRDS 1998 Annual Data Report, in, Bethesda, The National Institutes of Health, National Institute of Diabetes and Digestive Diseases, 1998
181. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458-482, 1990
182. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 49:1379-1385, 1996
183. Dart AM, Kingwell BA: Pulse pressure–a review of mechanisms and clinical relevance. J Am Coll Cardiol 37:975-984, 2001
184. Boutouyrie P, Bussy C, Lacolley P, Girerd X, Laloux B, Laurent S: Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 100:1387-1393, 1999
185. James MA, Watt PA, Potter JF, Thurston H, Swales JD: Pulse pressure and resistance artery structure in the elderly. Hypertension 26:301-306, 1995
186. Kozakova M, Morizzo C, Ferrannini E, Palombo C: Coronary vasodilator capacity and exercise-induced myocardial ischemia are related to the pulsatile component of blood pressure in patients with essential hypertension. J Hypertens 21:1407-1414, 2003
187. Christensen KL: Reducing pulse pressure in hypertension may normalize small artery structure. Hypertension 18:722-727, 1991
188. Tozawa M, Iseki K, Iseki C, Takishita S: Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 61:717-726, 2002
189. Blacher J, Asmar R, Djane S, London GM, Safar ME: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 33:1111-1117, 1999
190. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99:2434-2439, 1999
191. Avolio AP, Chen SG, Wang RP, Zhang CL, Li MF, O’Rourke MF: Effects of aging on changing arterial compliance and left ventricular load in a northern Chinese urban community. Circulation 68:50-58, 1983
192. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc’h PM, London GM: Central pulse pressure and mortality in end-stage renal disease. Hypertension 39:735-738, 2002
193. Asmar RG, Pannier B, Santoni JP, Laurent S, London GM, Levy BI, Safar ME: Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 78:941-950, 1988
194. London GM, Marchais SJ, Guerin AP, Metivier F, Safar ME, Fabiani F, Froment L: Salt and water retention and calcium blockade in uremia. Circulation 82:105-113, 1990
195. Guerin AP, Blacher J, Pannier B, Marchais SJ, Safar ME, London GM: Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103:987-992, 2001
196. Perloff D, Grim C, Flack J, Frohlich ED, Hill M, McDonald M, Morgenstern BZ: Human blood pressure determination by sphygmomanometry. Circulation 88:2460-2470, 1993
197. Gerin W, Schwartz AR, Schwartz JE, Pickering TG, Davidson KW, Bress J, O’Brien E, Atkins N: Limitations of current validation protocols for home blood pressure monitors for individual patients. Blood Press Monit 7:313-318, 2002
198. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
199. Rahman M, Griffin V, Kumar A, Manzoor F, Wright JT, Jr., Smith MC: A comparison of standardized versus "usual" blood pressure measurements in hemodialysis patients. Am J Kidney Dis 39:1226-1230, 2002
200. Conion PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwab SJ: Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol 7:2658-2663, 1996
201. Kooman JP, Gladziwa U, Bocker G, Wijnen JA, Bortel L, Luik AJ, de Leeuw PW, van Hoff JP, Leunissen KM: Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values. Nephrol Dial Transplant 7:917-923, 1992
202. Coomer RW, Schulman G, Breyer JA, Shyr Y: Ambulatory blood pressure monitoring in dialysis patients and estimation of mean interdialytic blood pressure. Am J Kidney Dis 29:678-684, 1997
203. Agarwal R, Lewis RR: Prediction of hypertension in chronic hemodialysis patients. Kidney Int 60:1982-1989, 2001
204. Millar-Craig MW, Bishop CN, Raftery EB: Circadian variation of blood-pressure. Lancet 1:795-797, 1978
205. National High Blood Pressure Education Program Working Group report on ambulatory blood pressure monitoring. Arch Intern Med 150:2270-2280, 1990
206. Mancia G, Ferrari A, Gregorini L, Parati G, Pomidossi G, Bertinieri G, Grassi G, di Rienzo M, Pedotti A, Zanchetti A: Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53:96-104, 1983
207. Shimada K, Kawamoto A, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T: Diurnal blood pressure variations and silent cerebrovascular damage in elderly patients with hypertension. J Hypertens 10:875-878, 1992
208. O’Brien E, Sheridan J, O’Malley K: Dippers and non-dippers. Lancet 2:397, 1988
209. Verdecchia P, Schillaci G, Guerrieri M, Gatteschi C, Benemio G, Boldrini F, Porcellati C: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81:528-536, 1990
210. Farmer CK, Goldsmith DJ, Cox J, Dallyn P, Kingswood JC, Sharpstone P: An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant 12:2301-2307, 1997
211. Baumgart P, Walger P, Gemen S, von Eiff M, Raidt H, Rahn KH: Blood pressure elevation during the night in chronic renal failure, hemodialysis and after renal transplantation. Nephron 57:293-298, 1991
212. Peixoto AJ, White WB: Ambulatory blood pressure monitoring in chronic renal disease: technical aspects and clinical relevance. Curr Opin Nephrol Hypertens 11:507-516, 2002
213. Ritz E, Schwenger V, Zeier M, Rychlik I: Ambulatory blood pressure monitoring: fancy gadgetry or clinically useful exercise? Nephrol Dial Transplant 16:1550-1554, 2001
214. Santos SF, Mendes RB, Santos CA, Dorigo D, Peixoto AJ: Profile of interdialytic blood pressure in hemodialysis patients. Am J Nephrol 23:96-105, 2003
215. Sokolow M, Werdegar D, Kain HK, Hinman AT: Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. Circulation 34:279-298, 1966
216. Agarwal R: Role of home blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 33:682-687, 1999
217. Perin PC, Maule S, Quadri R: Sympathetic nervous system, diabetes, and hypertension. Clin Exp Hypertens 23:45-55, 2001
218. O’Shea JC, Murphy MB: Nocturnal blood pressure dipping: a consequence of diurnal physical activity blipping? Am J Hypertens 13:601-606, 2000
219. Hanly PJ, Pierratos A: Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344:102-107, 2001
220. Zoccali C, Benedetto FA, Tripepi G, Cambareri F, Panuccio V, Candela V, Mallamaci F, Enia G, Labate C, Tassone F: Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int 53:1078-1084, 1998
221. Sorof JM, Brewer ED, Portman RJ: Ambulatory blood pressure monitoring and interdialytic weight gain in children receiving chronic hemodialysis. Am J Kidney Dis 33:667-674, 1999
222. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G: Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 96:1859-1862, 1997
223. Higashi Y, Oshima T, Ozono R, Nakano Y, Matsuura H, Kambe M, Kajiyama G: Nocturnal decline in blood pressure is attenuated by NaCl loading in salt-sensitive patients with essential hypertension: noninvasive 24-hour ambulatory blood pressure monitoring. Hypertension 30:163-167, 1997
224. Toth L, Voros P, Lengyel Z, Liptai M, Nemeth C, Kammerer L: Diurnal blood pressure variations in incipient and end stage diabetic renal disease. Diabetes Res Clin Pract 49:1-6, 2000
225. McGregor DO, Buttimore AL, Nicholls MG, Lynn KL: Ambulatory blood pressure monitoring in patients receiving long, slow home haemodialysis. Nephrol Dial Transplant 14:2676-2679, 1999
226. Fagugli RM, Reboldi G, Quintaliani G, Pasini P, Ciao G, Cicconi B, Pasticci F, Kaufman JM, Buoncristiani U: Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 38:371-376, 2001
227. Perloff D, Sokolow M, Cowan R: The prognostic value of ambulatory blood pressures. JAMA 249:2792-2798, 1983
228. Devereux RB, Pickering TG, Harshfield GA, Kleinert HD, Denby L, Clark L, Pregibon D, Jason M, Kleiner B, Borer JS, Laragh JH: Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress. Circulation 68:470-476, 1983
229. White WB, Schulman P, McCabe EJ, Dey HM: Average daily blood pressure, not office blood pressure, determines cardiac function in patients with hypertension. JAMA 261:873-877, 1989
230. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G: Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 5:93-98, 1987
231. Shimada K, Kawamoto A, Matsubayashi K, Ozawa T: Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 16:692-699, 1990
232. Peixoto AJ, Santos SF, Mendes RB, Crowley ST, Maldonado R, Orias M, Mansoor GA, White WB: Reproducibility of ambulatory blood pressure monitoring in hemodialysis patients. Am J Kidney Dis 36:983-990, 2000
233. Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, Salvador M, Chamontin B: Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int 57:2485-2491, 2000
234. Omboni S, Parati G, Palatini P, Vanasia A, Muiesan ML, Cuspidi C, Mancia G: Reproducibility and clinical value of nocturnal hypotension: prospective evidence from the SAMPLE study. Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation. J Hypertens 16:733-738, 1998
235. Horl MP, Horl WH: Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 39:227-244, 2002
236. Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW, Lewis JA, Lewis JL, Rocco MV: Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int 61:266-275, 2002
237. Chazot C, Charra B, Laurent G, Didier C, Vo Van C, Terrat JC, Calemard E, Vanel T, Ruffet M: Interdialysis blood pressure control by long haemodialysis sessions. Nephrol Dial Transplant 10:831-837, 1995
238. Katzarski KS, Charra B, Luik AJ, Nisell J, Divino Filho JC, Leypoldt JK, Leunissen KM, Laurent G, Bergstrom J: Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 14:369-375, 1999
239. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival as an index of adequacy of dialysis. Kidney Int 41:1286-1291, 1992
240. Ozkahya M, Toz H, Unsal A, Ozerkan F, Asci G, Gurgun C, Akcicek F, Mees EJ: Treatment of hypertension in dialysis patients by ultrafiltration: role of cardiac dilatation and time factor. Am J Kidney Dis 34:218-221, 1999
241. Kooistra MP, Vos J, Koomans HA, Vos PF: Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 13:2853-2860, 1998
242. Traeger J, Sibai-Galland R, Delawari E, Arkouche W: Daily versus standard hemodialysis: one year experience. Artif Organs 22:558-563, 1998
243. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM: Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 42:13-17, 2003
244. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61:2235-2239, 2002
245. Schalekamp MA, Schalekamp-Kuyken MP, de Moor-Fruytier M, Meininger T, Vaandrager-Kranenburg DJ, Birkenhager WH: Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. Clin Sci Mol Med 45:417-428, 1973
246. Schultze G, Piefke S, Molzahn M: Blood pressure in terminal renal failure. Fluid spaces and the renin-angiotensin-system. Nephron 25:15-24, 1980
247. Chan MK, Baillod RA, Chuah P, Sweny P, Raftery MJ, Varghese Z, Moorhead JF: Three years’ experience of continuous ambulatory peritoneal dialysis. Lancet 1:1409-1412, 1981
248. Saldanha LF, Weiler EW, Gonick HC: Effect of continuous ambulatory peritoneal dialysis on blood pressure control. Am J Kidney Dis 21:184-188, 1993
249. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
250. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
251. Adamson JW, Eschbach JW: Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 41:349-360, 1990
252. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351:1755-1762, 1998
253. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
254. Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, Charleston J, Cheek D, Cleveland W, Douglas JG, Douglas M, Dowie D, Faulkner M, Gabriel A, Gassman J, Greene T, Hall Y, Hebert L, Hiremath L, Jamerson K, Johnson CJ, Kopple J, Kusek J, Lash J, Lea J, Lewis JB, Lipkowitz M, Massry S, Middleton J, Miller ER, 3rd, Norris K, O’Connor D, Ojo A, Phillips RA, Pogue V, Rahman M, Randall OS, Rostand S, Schulman G, Smith W, Thornley-Brown D, Tisher CC, Toto RD, Wright JT, Jr., Xu S: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 285:2719-2728, 2001
255. 1995 update of the working group reports on chronic renal failure and renovascular hypertension. National High Blood Pressure Education Program Working Group. Arch Intern Med 156:1938-1947, 1996
256. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659-664, 1997
257. Paoletti E, Cassottana P, Bellino D, Specchia C, Messa P, Cannella G: Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 40:728-736, 2002
258. Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T: Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 90:256-261, 2002
259. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2002
260. Kestenbaum B, Gillen DL, Sherrard DJ, Seliger S, Ball A, Stehman-Breen C: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 61:2157-2164, 2002
261. Cirit M, Akcicek F, Terzioglu E, Soydas C, Ok E, Ozbasli CF, Basci A, Mees EJ: ‘Paradoxical’ rise in blood pressure during ultrafiltration in dialysis patients. Nephrol Dial Transplant 10:1417-1420, 1995
262. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291:451-459, 2004
263. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361:2024-2031, 2003
264. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1149-1158, 2003
265. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 138:98-104, 2003
266. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
267. Wanner C, Krane V, Marz W, Olschewski M, Asmus HG, Kramer W, Kuhn KW, Kutemeyer H, Mann JF, Ruf G, Ritz E: Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 27:259-266, 2004
268. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
269. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
270. Rozanski A, Blumenthal JA, Kaplan J: Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 99:2192-2217, 1999
271. Hensie LE, Campbell RJ: Psychiatric Dictionary, Oxford University Press, 1970
272. Blair SN, Kohl HW, 3rd, Paffenbarger RS, Jr., Clark DG, Cooper KH, Gibbons LW: Physical fitness and all-cause mortality. A prospective study of healthy men and women. JAMA 262:2395-2401, 1989
273. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN: The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med 130:89-96, 1999
274. Wei M, Gibbons LW, Kampert JB, Nichaman MZ, Blair SN: Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes. Ann Intern Med 132:605-611, 2000
275. Blair SN, Goodyear NN, Gibbons LW, Cooper KH: Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA 252:487-490, 1984
276. Office of the U.S. Surgeon General, Physical Activity and Health: A Report of the Surgeon General, in, U.S. Department of Health and Human Services, Public Health Service, 1996
277. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung and Blood Institute: Bethesda. Bethesda, MD, NHLBI, 1997
278. National Cholesterol Education Project, Third Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III), in, Bethesda, MD, NIH - NHLBI, 2000
279. DeOreo PB: Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis 30:204-212, 1997
280. Sietsema KE, Amato A, Adler SG, Brass EP: Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal disease. Kidney Int 65:719-724, 2004
281. Goldberg AP, Hagberg JM, Delmez JA, Heath GW, Harter HR: Exercise training improves abnormal lipid and carbohydrate metabolism in hemodialysis patients. Trans Am Soc Artif Intern Organs 25:431-437, 1979
282. Goldberg AP, Geltman EM, Hagberg JM, Gavin JR, Delmez 3rd, JA, Carney RM, Naumowicz A, Oldfield MH, Harter HR: Therapeutic benefits of exercise training for hemodialysis patients. Kidney Int Suppl 16:S303-309, 1983
283. Goldberg AP, Geltman EM, Gavin JR, Carney 3rd, RM, Hagberg JM, Delmez JA, Naumovich A, Oldfield MH, Harter HR: Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron 42:311-316, 1986
284. Deligiannis A, Kouidi E, Tassoulas E, Gigis P, Tourkantonis A, Coats A: Cardiac effects of exercise rehabilitation in hemodialysis patients. Int J Cardiol 70:253-266, 1999
285. Deligiannis A, Kouidi E, Tourkantonis A: Effects of physical training on heart rate variability in patients on hemodialysis. Am J Cardiol 84:197-202, 1999
286. Hagberg JM, Goldberg AP, Ehsani AA, Heath GW, Delmez JA, Harter HR: Exercise training improves hypertension in hemodialysis patients. Am J Nephrol 3:209-212, 1983
287. Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, Kent-Braun JA: Physical activity levels in patients on hemodialysis and healthy sedentary controls. Kidney Int 57:2564-2570, 2000
288. Johansen KL, Kaysen GA, Young BS, Hung AM, da Silva M, Chertow GM: Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr 77:842-846, 2003
289. Kouidi E, Albani M, Natsis K, Megalopoulos A, Gigis P, Guiba-Tziampiri O, Tourkantonis A, Deligiannis A: The effects of exercise training on muscle atrophy in haemodialysis patients. Nephrol Dial Transplant 13:685-699, 1998
290. Lo CY, Li L, Lo WK, Chan ML, So E, Tang S, Yuen MC, Cheng IK, Chan TM: Benefits of exercise training in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 32:1011-1018, 1998
291. Moore GE, Parsons DB, Stray-Gundersen J, Painter PL, Brinker KR, Mitchell JH: Uremic myopathy limits aerobic capacity in hemodialysis patients. Am J Kidney Dis 22:277-287, 1993
292. Painter PL, Nelson-Worel JN, Hill MM, Thornbery DR, Shelp WR, Harrington AR, Weinstein AB: Effects of exercise training during hemodialysis. Nephron 43:87-92, 1986
293. Painter P, Carlson L, Carey S, Paul SM, Myll J: Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. Am J Kidney Dis 35:482-492, 2000
294. Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, Haskell W: Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. Am J Kidney Dis 39:257-265, 2002
295. Shalom R, Blumenthal JA, Williams RS, McMurray RG, Dennis VW: Feasibility and benefits of exercise training in patients on maintenance dialysis. Kidney Int 25:958-963, 1984
296. Zabetakis PM, Gleim GW, Pasternack FL, Saraniti A, Nicholas JA, Michelis MF: Long-duration submaximal exercise conditioning in hemodialysis patients. Clin Nephrol 18:17-22, 1982
297. Akiba T, Matsui N, Shinohara S, Fujiwara H, Nomura T, Marumo F: Effects of recombinant human erythropoietin and exercise training on exercise capacity in hemodialysis patients. Artif Organs 19:1262-1268, 1995
298. Goldstein MG, Niaura R: Psychological factors affecting physical condition. Cardiovascular disease literature review. Part I: Coronary artery disease and sudden death. Psychosomatics 33:134-145, 1992
299. Booth-Kewley S, Friedman HS: Psychological predictors of heart disease: a quantitative review. Psychological Bulletin 101:343-362, 1987
300. Todaro JF, Shen BJ, Niaura R, Spiro A, Ward KD: Effect of negative emotions on frequency of coronary heart disease (The Normative Aging Study). Am J Cardiol 92: 901-906, 2003
301. Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Pyschiat 55:580-592, 1998
302. Sirois BC, Burg MM: Negative emotion and coronary heart disease: A review. Behav Modif 27 83-102, 2003
303. Kimmel PL, Weihs K, Peterson RA: Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol 4:12-27, 1993
304. Livesley WJ: Symptoms of anxiety and depression in patients undergoing chronic haemodialysis. J Psychosom Res 26:581-584, 1982
305. Kutner NG, Fair PL, Kutner MH: Assessing depression and anxiety in chronic dialysis patients. J Psychosom Res 29:23-31, 1985
306. Lopes AA, Albert JM, Young EW, Satayathum S, Pisoni RL, Andreucci VE, Mapes DL, Mason NA, Fukuhara S, Wikstrom B, Saito A, Port FK: Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 66:2047-2053, 2004
307. Medalie JH, Goldbourt U: Angina pectoris among 10,000 men. II. Psychosocial and other risk factors as evidenced by a multivariate analysis of a five year incidence study. Am J Med 60:910-921, 1976
308. Strik JJ, Denollet J, Lousberg R, Honig A: Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol 42:1801-1807, 2003
309. Russek LG, King SH, Russek SJ, Russek HI: The Harvard Mastery of Stress Study 35-year follow-up: prognostic significance of patterns of psychophysiological arousal and adaptation. Psychosom Med 52:271-285, 1990
310. Verrier RL, Mittelman MA: Cardiovascular consequences of anger and other stress states. Baillieres Clinical Neurology 6:245-259, 1997
311. Suinn RM: The terrible twos–anger and anxiety. Hazardous to your health. Am Psychol 56:27-36, 2001
312. Fava M, Serafini E, De Besi L, Adami A, Mastrogiacomo, I.: Hyperprolactinemia and psychological distress in women undergoing chronic hemodialysis. Psychother Psychosom 49:6-9, 1988
313. White Y, Grenyer BF: The biopsychosocial impact of end-stage renal disease: the experience of dialysis patients and their partners. J Adv Nurs 30:1312-1320, 1999
314. Joynt KE, Whellan DJ, O’Connor CM: Depression and cardiovascular disease: mechanisms of interaction. Biol Psychiatry 54:248-261, 2003
315. Benedict RH, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B: Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler 9:393-396, 2003
316. Annotated Bibliography of the WHO Quality of Life Assessment Instrument–WHOQOL. Geneva, Switzerland, Department of Mental Health, WHO, 1998
317. Alarcon RD, Jenkins CS, Heestand DE, Scott LK, Cantor L: The effectiveness of progressive relaxation in chronic hemodialysis patients. J Chronic Dis 35:797-802, 1982
318. Mayne TJ, Ambrose TK: Research review on anger in psychotherapy. J Clin Psychol 55:353-363, 1999
319. Matthews KA, Haynes SG: Type A behavior pattern and coronary disease risk. Update and critical evaluation. Am J Epidemiol 123:923-960, 1986
320. Klang B, Bjorvell H, Berglund J, Sundstedt C, Clyne N: Predialysis patient education: effects on functioning and well-being in uraemic patients. J Adv Nurs 28:36-44, 1998
321. Kimmel PL: Depression as a mortality risk factor in hemodialysis patients. Int J Artif Organs 15:697-700, 1992
322. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658, 1999
323. Bloembergen WE, Stannard DC, Port FK, Wolfe RA, Pugh JA, Jones CA, Greer JW, Golper TA, Held PJ: Relationship of dose of hemodialysis and cause-specific mortality. Kidney Int 50:557-565, 1996
324. Tepel M, vander Giet M, Park A, Zidek W: Association of calcium channel blockers and mortality in haemodialysis patients. Clinical Science 103:511-515, 2002
325. Fleischmann EH, Bower JD, Salahudeen AK: Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? Clin Nephrol 56:221-230, 2001
326. Kimura G, Tomita J, Nakamura S, Uzu T, Inenaga T: Interaction between hypertension and other cardiovascular risk factors in survival of hemodialyzed patients. Am J Hypertens 9:1006-1012, 1996
327. Mallamaci F, Zoccali C, Tripepi G, Fermo I, Benedetto FA, Cataliotti A, Bellanuova I, Malatino LS, Soldarini A, The C, I: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61:609-614, 2002
328. Fung F, Sherrard DJ, Gillen DL, Wong C, Kestenbaum B, Seliger S, Ball A, Stehman-Breen C: Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. Am J Kidney Dis 40:307-314, 2002
329. Brown JH, Hunt LP, Vites NP, Short CD, Gokal R, Mallick NP: Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 9:1136-1142, 1994
330. Rostand SG, Kirk KA, Rutsky EA: Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease. Kidney Int 22:304-308, 1982
331. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53-61, 1996
332. Besarab A, Bolton WK, Nissenson AR, Schwab SJ, Goodkin DA: The Normal Haematocrit Trial in dialysis patients with cardiac disease. Nephrol Dial Transplant 14:2043-2044, 1999
333. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325-1335, 2000
334. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H: Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 17:1713-1724, 2002
335. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
336. Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T: Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 17:1513-1517, 2002
337. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27:394-401, 1996
338. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R: Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 15:827-832, 1990
339. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695-701, 2002
340. O’Rourke RA, Brundage BH, Froelicher VF, Greenland P, Grundy SM, Hachamovitch R, Pohost GM, Shaw LJ, Weintraub WS, Winters WL, Jr.: American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. J Am Coll Cardiol 36:326-340, 2000
341. Moe SM, O’Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, Meyer CA: Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 18:1152-1158, 2003
342. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15:1014-1021, 2000
343. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938-942, 2001
344. Joy MS, Finn WF: Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42:96-107, 2003
345. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037-2040, 1998
346. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE: Cardiac valve calcification as an important predictor for all cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients. J Am Soc Nephrol 13:159-168, 2003
347. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617, 1998
348. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK: Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
349. Moe SM, O’Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61:638-647, 2002
350. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:E10-17, 2000
351. Giachelli CM: Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol 14:S300-304, 2003 (suppl 4)
352. Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63:1296-1301, 2003
353. Kurz P, Monier-Faugere MC, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861, 1994
354. Carmen Sanchez M, Auxiliadora Bajo M, Selgas R, Mate A, Millan I, Eugenia Martinez M, Lopez-Barea F: Parathormone secretion in peritoneal dialysis patients with adynamic bone disease. Am J Kidney Dis 36:953-961, 2000
355. Guh JY, Chen HC, Chuang HY, Huang SC, Chien LC, Lai YH: Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 39:1245-1254, 2002
356. McIntyre CW, Patel V, Taylor GS, Fluck RJ: A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol Dial Transplant 17:1643-1648, 2002
357. Kronenberg F, Mundle M, Langle M, Neyer U: Prevalence and progression of peripheral arterial calcifications in patients with ESRD. Am J Kidney Dis 41:140-148, 2003
358. De Lima JJ, Lopes HF, Grupi CJ, Abensur H, Giorgi MC, Krieger EM, Pileggi F: Blood pressure influences the occurrence of complex ventricular arrhythmia in hemodialysis patients. Hypertension 26:1200-1203, 1995
359. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117, 2001
360. Lundin AP, Adler 3rd, AJ, Feinroth MV, Berlyne GM, Friedman EA: Maintenance hemodialysis. Survival beyond the first decade. JAMA 244:38-40, 1980
361. Fernandez-Reyes MJ, Auxiliadora Bajo M, Robles P, Selgas R, Oliver J, Del Peso G, Garcia G, Jimenez C, Garcia-Gallego F: Mitral annular calcification in CAPD patients with a low degree of hyperparathyroidism. An analysis of other possible risk factors. Nephrol Dial Transplant 10:2090-2095, 1995
362. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627-636, 1998
363. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12:1508-1515, 2001
364. Port FK, Hulbert-Shearon TE, Wolfe RA, Bloembergen WE, Golper TA, Agodoa LY, Young EW: Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33:507-517, 1999
365. Schreiber MJ, Jr.: Setting the stage. Am J Kidney Dis 38:S1-S10, 2001 (suppl 4)
366. Calvo C, Maule S, Mecca F, Quadri R, Martina G, Cavallo Perin P: The influence of autonomic neuropathy on hypotension during hemodialysis. Clin Auton Res 12:84-87, 2002
367. Kooman JP, Gladziwa U, Bocker G, van Bortel LM, van Hooff JP, Leunissen KM: Role of the venous system in hemodynamics during ultrafiltration and bicarbonate dialysis. Kidney Int 42:718-726, 1992
368. Converse RL, Jr., Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, Fouad-Tarazi F, Victor RG: Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 90:1657-1665, 1992
369. van der Sande FM, Kooman JP, Burema JH, Hameleers P, Kerkhofs AM, Barendregt JM, Leunissen KM: Effect of dialysate temperature on energy balance during hemodialysis: quantification of extracorporeal energy transfer. Am J Kidney Dis 33:1115-1121, 1999
370. Rosales LM, Schneditz D, Morris AT, Rahmati S, Levin NW: Isothermic hemodialysis and ultrafiltration. Am J Kidney Dis 36:353-361, 2000
371. Jost CM, Agarwal R, Khair-el-Din T, Grayburn PA, Victor RG, Henrich WL: Effects of cooler temperature dialysate on hemodynamic stability in "problem" dialysis patients. Kidney Int 44:606-612, 1993
372. Maggiore Q, Dattolo P, Piacenti M, Morales MA, Pelosi G, Pizzarelli F, Cerrai T: Thermal balance and dialysis hypotension. Int J Artif Organs 18:518-525, 1995
373. Levy FL, Grayburn PA, Foulks CJ, Brickner ME, Henrich WL: Improved left ventricular contractility with cool temperature hemodialysis. Kidney Int 41:961-965, 1992
374. van Kuijk WH, Luik AJ, de Leeuw PW, van Hooff JP, Nieman FH, Habets HM, Leunissen KM: Vascular reactivity during haemodialysis and isolated ultrafiltration: thermal influences. Nephrol Dial Transplant 10:1852-1858, 1995
375. van der Sande FM, Kooman JP, Konings CJ, Leunissen KM: Thermal effects and blood pressure response during postdilution hemodiafiltration and hemodialysis: the effect of amount of replacement fluid and dialysate temperature. J Am Soc Nephrol 12:1916-1920, 2001
376. Maggiore Q, Pizzarelli F, Santoro A, Panzetta G, Bonforte G, Hannedouche T, Alvarez de Lara MA, Tsouras I, Loureiro A, Ponce P, Sulkova S, Van Roost G, Brink H, Kwan JT: The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial. Am J Kidney Dis 40:280-290, 2002
377. Fine A, Penner B: The protective effect of cool dialysate is dependent on patients’ predialysis temperature. Am J Kidney Dis 28:262-265, 1996
378. Henrich WL, Hunt JM, Nixon JV: Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 310:19-23, 1984
379. van der Sande FM, Cheriex EC, van Kuijk WH, Leunissen KM: Effect of dialysate calcium concentrations on intradialytic blood pressure course in cardiac-compromised patients. Am J Kidney Dis 32:125-131, 1998
380. Lang RM, Fellner SK, Neumann A, Bushinsky DA, Borow KM: Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 108:524-529, 1988
381. Henrich WL: Hemodynamic instability during hemodialysis. Kidney Int 30:605-612, 1986
382. Beige J, Sone J, Sharma AM, Rudwaleit M, Offermann G, Distler A, Preuschof L: Computational analysis of blood volume curves and risk of intradialytic morbid events in hemodialysis. Kidney Int 58:1805-1809, 2000
383. de Vries PM, Olthof CG, Solf A, Schuenemann B, Oe PL, Quellhorst E, Schneider H, Donker AJ: Fluid balance during haemodialysis and haemofiltration: the effect of dialysate sodium and a variable ultrafiltration rate. Nephrol Dial Transplant 6:257-263, 1991
384. Flanigan MJ: Role of sodium in hemodialysis. Kidney Int Suppl 76:S72-78, 2000
385. Mann H, Stiller S: Sodium modeling. Kidney Int Suppl 76:S79-88, 2000
386. Sang GL, Kovithavongs C, Ulan R, Kjellstrand CM: Sodium ramping in hemodialysis: a study of beneficial and adverse effects. Am J Kidney Dis 29:669-677, 1997
387. Ligtenberg G, Barnas MG, Koomans HA: Intradialytic hypotension: new insights into the mechanism of vasovagal syncope. Nephrol Dial Transplant 13:2745-2747, 1998
388. van Kuijk WH, Wirtz JJ, Grave W, de Heer F, Menheere PP, van Hooff JP, Leunissen KM: Vascular reactivity during combined ultrafiltration-haemodialysis: influence of dialysate sodium. Nephrol Dial Transplant 11:323-328, 1996
389. Oliver MJ, Edwards LJ, Churchill DN: Impact of sodium and ultrafiltration profiling on hemodialysis-related symptoms. J Am Soc Nephrol 12:151-156, 2001
390. Cavalcanti S, Cavani S, Santoro A: Role of short-term regulatory mechanisms on pressure response to hemodialysis-induced hypovolemia. Kidney Int 61:228-238, 2002
391. Coli L, Ursino M, De Pascalis A, Brighenti C, Dalmastri V, La Manna G, Isola E, Cianciolo G, Patrono D, Boni P, Stefoni S: Evaluation of intradialytic solute and fluid kinetics. Setting up a predictive mathematical model. Blood Purif 18:37-49, 2000
392. Cruz DN: Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension. Expert Opin Pharmacother 1:835-840, 2000
393. Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA: Midodrine is effective and safe therapy for intradialytic hypotension over 8 months of follow-up. Clin Nephrol 50:101-107, 1998
394. Blowey DL, Balfe JW, Gupta I, Gajaria MM, Koren G: Midodrine efficacy and pharmacokinetics in a patient with recurrent intradialytic hypotension. Am J Kidney Dis 28:132-136, 1996
395. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM: Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 95:38-48, 1993
396. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA: A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 51:120-124, 1998
397. Bellinghieri G, Santoro D, Calvani M, Mallamace A, Savica V: Carnitine and hemodialysis. Am J Kidney Dis 41:S116-122, 2003 (suppl 1)
398. Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA, Hirschberg R, Nicora R, Ashbrook DW, Kopple JD: Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects. Kidney Int 38:912-918, 1990
399. Riley S, Rutherford S, Rutherford PA: Low carnitine levels in hemodialysis patients: relationship with functional activity status and intra-dialytic hypotension. Clin Nephrol 48:392-393, 1997
400. Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A: Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 33:1227-1230, 1999
401. Grubb BP, Samoil D, Kosinski D, Kip K, Brewster P: Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents. J Am Coll Cardiol 24:490-494, 1994
402. Dheenan S, Venkatesan J, Grubb BP, Henrich WL: Effect of sertraline hydrochloride on dialysis hypotension. Am J Kidney Dis 31:624-630, 1998
403. Yalcin AU, Sahin G, Erol M, Bal C: Sertraline hydrochloride treatment for patients with hemodialysis hypotension. Blood Purif 20:150-153, 2002
404. Yalcin AU, Kudaiberdieva G, Sahin G, Gorenek B, Akcar N, Kuskus S, Bayrak F, Timuralp B: Effect of sertraline hydrochloride on cardiac autonomic dysfunction in patients with hemodialysis-induced hypotension. Nephron Physiol 93:P21-28, 2003
405. Davison AM, Roberts TG, Mascie-Taylor BH, Lewins AM: Haemofiltration for profound dialysis-induced hypotension: removal of sodium and water without blood-pressure change. Br Med J (Clin Res Ed) 285:87-89, 1982
406. van Der Sande FM, Kooman JP, Leunissen KM: Strategies for improving hemodynamic stability in cardiac-compromised dialysis patients. Am J Kidney Dis 35:E19, 2000
407. Krepel HP, Nette RW, Akcahuseyin E, Weimar W, Zietse R: Variability of relative blood volume during haemodialysis. Nephrol Dial Transplant 15:673-679, 2000
408. Chan CT, Harvey PJ, Picton P, Pierratos A, Miller JA, Floras JS: Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 42:925-931, 2003
409. Chan CT: Cardiovascular effects of frequent intensive hemodialysis. Semin Dial 17:99-103, 2004
410. McCormick BB, Chan CT: Improved blood pressure control with nocturnal hemodialysis: review of clinical observations and physiologic mechanisms. Curr Hypertens Rep 6:140-144, 2004
411. Apple FSP, Murakami MMB, Pearce LAM, Herzog CAM: Predictive Value of Cardiac Troponin I and T for Subsequent Death in End-Stage Renal Disease. Circulation 106:2941-2945, 2002
412. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W: Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 290:353-359, 2003
413. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS: Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 40:68-75, 2002
414. Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, Ishikawa T, Kurokawa H, Hirano T, Kondo T, Nagamura Y, Ezaki K, Hishida H: Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 312:69-79, 2001
415. Lang K, Schindler S, Forberger C, Stein G, Figulla HR: Cardiac troponins have no prognostic value for acute and chronic cardiac events in asymptomatic patients with end-stage renal failure. Clin Nephrol 56:44-51, 2001
416. Porter GA, Norton T, Bennett WM: Long term follow up of the utility of troponin T to assess cardiac risk in stable chronic hemodialysis patients. Clin Lab 46:469-476, 2000
417. Roppolo LP, Fitzgerald R, Dillow J, Ziegler T, Rice M, Maisel A: A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran’s Hospital: a pilot study. J Am Coll Cardiol 34:448-454, 1999
418. Ooi DS, Veinot JP, Wells GA, House AA: Increased mortality in hemodialyzed patients with elevated serum troponin T: a one-year outcome study. Clin Biochem 32:647-652, 1999
419. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C: Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102:1964-1969, 2000
420. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 62:1791-1798, 2002
421. Menon V, Wang X, Greene T, Beck GJ, Kusek JW, Marcovina SM, Levey AS, Sarnak MJ: Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 42:44-52, 2003
422. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35:469-476, 2000
423. Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, Han DS: Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 18:387-394, 1998
424. Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14:1956-1960, 1999
425. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107:87-92, 2003
426. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, Stenvinkel P: Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 41:1212-1218, 2003
427. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, Sanderson JE: Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 15:2186-2194, 2004
428. Ayus JC, Sheikh-Hamad D: Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 9:1314-1317, 1998
429. Lopez-Gomez JM, Perez-Flores I, Jofre R, Carretero D, Rodriguez-Benitez P, Villaverde M, Perez-Garcia R, Nassar GM, Niembro E, Ayus JC: Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 15:2494-2501, 2004
430. Libby P: Inflammation in atherosclerosis. Nature 420:868-874, 2002
431. Stenvinkel P, Heimburger O, Jogestrand T, Karnell A, Samuelsson A: Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? Kidney Int 55:2531-2532, 1999
432. Wolf SC, Mayer O, Jurgens S, Vonthein R, Schultze G, Risler T, Brehm BR: Chlamydia pneumoniae IgA seropositivity is associated with increased risk for atherosclerotic vascular disease, myocardial infarction and stroke in dialysis patients. Clin Nephrol 59:273-279, 2003
433. Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ: Septicemia in the United States dialysis population, 1991 to 1999. J Am Soc Nephrol 15:1038-1045, 2004
434. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T: Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55:1899-1911, 1999
435. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Fermo I, Foca A, Paroni R, Malatino LS: Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients. J Hypertens 18:1207-1213, 2000
436. Koenig W: C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrol Dial Transplant 18:1039-1041, 2003
437. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361:827-833, 2003
438. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM: C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 62:1417-1422, 2002
439. Wang AY, Woo J, Lam CW, Wang M, Sea MM, Lui SF, Li PK, Sanderson J: Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 14:1871-1879, 2003
440. Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, Sturtevant JM, Isbel NM, Nicol DL, Johnson DW: Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 12:814-821, 2001
441. Pifer TB, McCullough KP, Port FK, Goodkin DA, Maroni BJ, Held PJ, Young EW: Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 62:2238-2245, 2002
442. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O’Shea S, Owen WF, Jr., Lowrie EG: White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 18:1167-1173, 2003
443. Kaysen GA, Dubin JA, Muller HG, Rosales LM, Levin NW: The acute-phase response varies with time and predicts serum albumin levels in hemodialysis patients. The HEMO Study Group. Kidney Int 58:346-352, 2000
444. Haubitz M, Brunkhorst R: C-reactive protein and chronic Chlamydia pneumoniae infection–long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 16:809-815, 2001
445. Stenvinkel P, Barany P, Chung SH, Lindholm B, Heimburger O: A comparative analysis of nutritional parameters as predictors of outcome in male and female ESRD patients. Nephrol Dial Transplant 17:1266-1274, 2002
446. Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimburger O, Lindholm B, Bergstrom J: Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 13:S28-36, 2002 (suppl 1)
447. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
448. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272-1280, 2003
449. Stenvinkel P: Interactions between inflammation, oxidative stress, and endothelial dysfunction in end-stage renal disease. J Ren Nutr 13:144-148, 2003
450. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL: Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286:2136-2142, 2001
451. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108:1440-1445, 2003
452. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349:1595-1604, 2003
453. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59:1960-1966, 2001
454. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J: Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 58:190-197, 2002
455. Salomon RG, Batyreva E, Kaur K, Sprecher DL, Schreiber MJ, Crabb JW, Penn MS, DiCorletoe AM, Hazen SL, Podrez EA: Isolevuglandin-protein adducts in humans: products of free radical-induced lipid oxidation through the isoprostane pathway. Biochim Biophys Acta 1485:225-235, 2000
456. Banni S, Lucchi L, Baraldi A, Botti B, Cappelli G, Corongiu F, Dessi MA, Tomasi A, Lusvarghi E: No direct evidence of increased lipid peroxidation in hemodialysis patients. Nephron 72:177-183, 1996
457. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. QJM 87:679-683, 1994
458. Salomon RG, Kaur K, Podrez E, Hoff HF, Krushinsky AV, Sayre LM: HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem Res Toxicol 13:557-564, 2000
459. Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten ML, Loseto-Wich G, Jurgens G, Heinecke J, Sevanian A: Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 274:18916-18924, 1999
460. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW: Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 31:1163-1169, 2001
461. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillere-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P, Drueke T, Descamps-Latscha B: Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524-2532, 1998
462. Tarng DC, Huang TP, Wei YH, Liu TY, Chen HW, Wen Chen T, Yang WC: 8-hydroxy-2’-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients. Am J Kidney Dis 36:934-944, 2000
463. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104:2673-2678, 2001
464. Shoji T, Fukumoto M, Kimoto E, Shinohara K, Emoto M, Tahara H, Koyama H, Ishimura E, Nakatani T, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y: Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 62:2230-2237, 2002
465. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, Gausson V, London GM: Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106:2212-2217, 2002
466. Kaneda H, Taguchi J, Ogasawara K, Aizawa T, Ohno M: Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162:221-225, 2002
467. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B: Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 12:2747-2752, 2001
468. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 16:1189-1197, 2001
469. Boaz M, Matas Z, Biro A, Katzir Z, Green M, Fainaru M, Smetana S: Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kidney Int 56:1078-1083, 1999
470. Bayes B, Pastor MC, Bonal J, Junca J, Hernandez JM, Riutort N, Foraster A, Romero R: Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 18:106-112, 2003
471. Stenvinkel P, Diczfalusy U, Lindholm B, Heimburger O: Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant 19:972-976, 2004
472. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M: Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16:335-340, 2001
473. Mezzano D, Pais EO, Aranda E, Panes O, Downey P, Ortiz M, Tagle R, Gonzalez F, Quiroga T, Caceres MS, Leighton F, Pereira J: Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 60:1844-1850, 2001
474. Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S, Phinney S, Miller G: Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int 64:978-991, 2003
475. Stenvinkel P, Holmberg I, Heimburger O, Diczfalusy U: A study of plasmalogen as an index of oxidative stress in patients with chronic renal failure. Evidence of increased oxidative stress in malnourished patients. Nephrol Dial Transplant 13:2594-2600, 1998
476. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, van Ypersele de Strihou C, Maeda K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198-1206, 1996
477. Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC: Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 106:2919-2924, 2002
478. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997
479. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 7:728-736, 1996
480. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ: Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361:2017-2023, 2003
481. Hodis HN, Mack WJ, LaBree L, Mahrer PR, Sevanian A, Liu CR, Liu CH, Hwang J, Selzer RH, Azen SP: Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation 106:1453-1459, 2002
482. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347:781-786, 1996
483. Salonen R, Nyssonen K, Porkkala-Sarataho E, Salonen JT: The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 76:34C-39C, 1995
484. Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105:2107-2111, 2002
485. Islam KN, O’Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I: Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 150:217-224, 2000
486. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canaud B: Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 12:2312-2317, 1997
487. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
488. Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, Bosch J, Dagenais GR, Yusuf S: Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 65:1375-1380, 2004
489. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107:992-995, 2003
490. Tarng DC, Liu TY, Huang TP: Protective effect of vitamin C on 8-hydroxy-2’-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. Kidney Int 66:820-831, 2004
491. Ward RA, McLeish KR: Hemodialysis with cellulose membranes primes the neutrophil oxidative burst. Artif Organs 19:801-807, 1995
492. Satoh M, Yamasaki Y, Nagake Y, Kasahara J, Hashimoto M, Nakanishi N, Makino H: Oxidative stress is reduced by the long-term use of vitamin E-coated dialysis filters. Kidney Int 59:1943-1950, 2001
493. Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T: Hemodialysis impairs endothelial function via oxidative stress: effects of vitamin E-coated dialyzer. Circulation 101:1002-1006, 2000
494. Girndt M, Lengler S, Kaul H, Sester U, Sester M, Kohler H: Prospective crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction. Am J Kidney Dis 35:95-104, 2000
495. Ward RA, Ouseph R, McLeish KR: Effects of high-flux hemodialysis on oxidant stress. Kidney Int 63:353-359, 2003
496. Siems W, Carluccio F, Grune T, Jakstadt M, Quast S, Hampl H, Sommerburg O: Elevated serum concentration of cardiotoxic lipid peroxidation products in chronic renal failure in relation to severity of renal anemia. Clin Nephrol 58:S20-25, 2002 (suppl 1)
497. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40:1005-1012, 2002
498. National Heart LaBI: Clinical Guidelines on the Identification, Evaluation and Treatment of Overweight and Obesity in Adults. Bethesda, MD, National Institutes of Health, 1998
499. Hakim RM, Lowrie E: Obesity and mortality in ESRD: is it good to be fat? Kidney Int 55:1580-1581, 1999
500. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58:353-362, 2000
501. Kopple JD: Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. ASAIO J 43:246-250, 1997
502. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35:S117-131, 2000 (suppl 1)
503. Beddhu S, Pappas LM, Ramkumar N, Samore M: Effects of body size and body composition on survival in hemodialysis patients. J Am Soc Nephrol In Press, 2004
504. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial. JAMA 281:1275-1281, 1999
505. Sardesai VM: Biochemical and nutritional aspects of eicosanoids. J Nutr Biochem 3:562-579, 1992
506. Dietary Reference Intakes for Energy, Carbohydrates, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids (Macronutrients) (vol 8). Washington, DC, The National Academies Press, 2002
507. Hu FB, Willett WC: Optimal diets for prevention of coronary heart disease. JAMA 288:2569-2578, 2002
508. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747-2757, 2002
509. Simopoulos AP: Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 54:438-463, 1991
510. Marckmann P, Gronbaek M: Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies. Eur J Clin Nutr 53:585-590, 1999
511. Harris WS, Park Y, Isley WL: Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol 14:9-14, 2003
512. Goldstein DJ, Wheeler DC, Salant DJ: Effects of omega-3 fatty acids on complement-mediated glomerular epithelial cell injury. Kidney Int 50:1863-1871, 1996
513. Vanschoonbeek K, de Maat MP, Heemskerk JW: Fish oil consumption and reduction of arterial disease. J Nutr 133:657-660, 2003
514. Blok WL, Katan MB, van der Meer JW: Modulation of inflammation and cytokine production by dietary (n-3) fatty acids. J Nutr 126:1515-1533, 1996
515. Abe Y, El-Masri B, Kimball KT, Pownall H, Reilly CF, Osmundsen K, Smith CW, Ballantyne CM: Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion. Arterioscler Thromb Vasc Biol 18:723-731, 1998
516. De Caterina R, Libby P: Control of endothelial leukocyte adhesion molecules by fatty acids. Lipids 31:S57-63, 1996 (suppl)
517. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J: Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346:1113-1118, 2002
518. Leaf A, Kang JX, Xiao YF, Billman GE: Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107:2646-2652, 2003
519. Stone NJ, Van Horn L: Therapeutic lifestyle change and Adult Treatment Panel III: evidence then and now. Curr Atheroscler Rep 4:433-443, 2002
520. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW, Jr., Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL: AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 102:2284-2299, 2000
521. Saltissi D, Morgan C, Knight B, Chang W, Rigby R, Westhuyzen J: Effect of lipid-lowering dietary recommendations on the nutritional intake and lipid profiles of chronic peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 37:1209-1215, 2001
522. Hall AV, Parbtani A, Clark WF, Spanner E, Huff MW, Philbrick DJ, Holub BJ: Omega-3 fatty acid supplementation in primary nephrotic syndrome: effects on plasma lipids and coagulopathy. J Am Soc Nephrol 3:1321-1329, 1992
523. Sirajeddine K, Richard MJ, Cordonnier D: Omega-3 fatty acids in haemodialysis patients. Nephrol Dial Transplant 6:526, 1991
524. Rylance PB, George MP, Saynor R, Weston MJ: A pilot study of the use of MaxEPA in haemodialysis patients. Br J Clin Pract Suppl 31:49-54, 1984
525. Lossl K, Skou HA, Christensen JH, Schmidt EB: The effect of n-3 fatty acids on leukotriene formation from neutrophils in patients on hemodialysis. Lipids 34:S185, 1999 (suppl)
526. Christensen JH, Aaroe J, Knudsen N, Dideriksen K, Kornerup HJ, Dyerberg J, Schmidt EB: Heart rate variability and n-3 fatty acids in patients with chronic renal failure–a pilot study. Clin Nephrol 49:102-106, 1998
527. Iorio L, Saltarelli G, Nacca RG, Simonelli R, Violi F: Hyperlipidemia in dialysis patients: what treatment? Miner Electrolyte Metab 23:311-313, 1997
528. Persichetti S, Maggi S, Ponzio R, Punzo G, Clemenzia G, Cottone G: Effects of omega 3-PUFA on plasma fibrinogen levels in hypertriglyceridemic hemodialysis patients. Minerva Urol Nefrol 48:137-138, 1996
529. Bonanome A, Biasia F, De Luca M, Munaretto G, Biffanti S, Pradella M, Pagnan A: n-3 fatty acids do not enhance LDL susceptibility to oxidation in hypertriacylglycerolemic hemodialyzed subjects. Am J Clin Nutr 63:261-266, 1996
530. Dionisio P, Caramello E, Bergia R, Valenti M, Cornella C, Pagni R, Bajardi P: Atherogenic risk in patients undergoing regular dialysis treatment: improvement of lipid pattern and lipoproteins by polyunsaturated omega-3 fatty acids. Nephrol Dial Transplant 9:458, 1994
531. Kutner NG, Clow PW, Zhang R, Aviles X: Association of fish intake and survival in a cohort of incident dialysis patients. Am J Kidney Dis 39:1018-1024, 2002
532. Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J: Long-term prognosis of hypertension in pregnancy. Hypertens Pregnancy 19:199-209, 2000
533. Keebler ME, De Souza C, Fonseca V: Diagnosis and treatment of hyperhomocysteinemia. Curr Atheroscler Rep 3:54-63, 2001
534. Klee GG: Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B(12) and folate. Clin Chem 46:1277-1283, 2000
535. Amores-Sanchez MI, Medina MA: Methods for the determination of plasma total homocysteine: a review. Clin Chem Lab Med 38:199-204, 2000
536. Powers HJ, Moat SJ: Developments in the measurement of plasma total homocysteine. Curr Opin Clin Nutr Metab Care 3:391-397, 2000
537. McKinley MC: Nutritional aspects and possible pathological mechanisms of hyperhomocysteinaemia: an independent risk factor for vascular disease. Proc Nutr Soc 59:221-237, 2000
538. Brattstrom L, Wilcken DE: Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr 72:315-323, 2000
539. Ueland PM, Refsum H, Beresford SA, Vollset SE: The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324-332, 2000
540. Graham IM, O’Callaghan P: The role of folic acid in the prevention of cardiovascular disease. Curr Opin Lipidol 11:577-587, 2000
541. Andreotti F, Burzotta F, Manzoli A, Robinson K: Homocysteine and risk of cardiovascular disease. J Thromb Thrombolysis 9:13-21, 2000
542. Young IS, Woodside JV: Folate and homocysteine. Curr Opin Clin Nutr Metab Care 3:427-432, 2000
543. Coppola A, Davi G, De Stefano V, Mancini FP, Cerbone AM, Di Minno G: Homocysteine, coagulation, platelet function, and thrombosis. Semin Thromb Hemost 26:243-254, 2000
544. Gambhir DS: Homocysteinemia and risk for cardiovascular disease. Indian Heart J 52:S2-4, 2000 (suppl 7)
545. Tsai MY: Moderate hyperhomocysteinemia and cardiovascular disease. J Lab Clin Med 135:16-25, 2000
546. Booth GL, Wang EE: Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. Can Med Assoc J 163:21-29, 2000
547. Blacher J, Safar ME: Homocysteine, folic acid, B vitamins and cardiovascular risk. J Nutr Health Aging 5:196-199, 2001
548. Perna AF, Ingrosso D, Castaldo P, Galletti P, De Santo NG: Homocysteine and transmethylations in uremia. Kidney Int Suppl 78:S230-233, 2001
549. Ducloux D, Motte G, Challier B, Gibey R, Chalopin JM: Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol 11:134-137, 2000
550. Massy ZA: Importance of homocysteine, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant 15:81-91, 2000 (suppl 5)
551. van Guldener C, Robinson K: Homocysteine and renal disease. Semin Thromb Hemost 26:313-324, 2000
552. Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, London GM: Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int 57:1091-1099, 2000
553. Sakurabayashi T, Fujimoto M, Takaesu Y, Haginoshita S, Goto S, Aoike I, Miyazaki S, Koda Y, Yuasa Y, Sakai S, Suzuki M, Hirasawa Y: Association between plasma homocysteine concentration and carotid atherosclerosis in hemodialysis patients. Jpn Circ J 63:692-696, 1999
554. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM: Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 12:248-255, 1999
555. Kunz K, Petitjean P, Lisri M, Chantrel F, Koehl C, Wiesel ML, Cazenave JP, Moulin B, Hannedouche TP: Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol Dial Transplant 14:1934-1942, 1999
556. Lee YK, Kwon YJ, Yoon JW, Oh KS, Cha DR, Cho WY, Huh K, Pyo HJ, Kim HK: Homocyst(e)ine and atherosclerosis in patients on chronic hemodialysis. J Korean Med Sci 14:193-198, 1999
557. Vychytil A, Fodinger M, Wolfl G, Enzenberger B, Auinger M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter C, Horl WH, Sunder-Plassmann G: Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 53:1775-1782, 1998
558. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM: Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18:535-541, 1998
559. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH: Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17:2554-2558, 1997
560. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94:2743-2748, 1996
561. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6:121-125, 1995
562. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP: An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int 60:1106-1113, 2001
563. Kennedy R, Case C, Fathi R, Johnson D, Isbel N, Marwick TH: Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am J Med 110:198-204, 2001
564. Oishi K, Nagake Y, Yamasaki H, Fukuda S, Ichikawa H, Ota K, Makino H: The significance of serum homocysteine levels in diabetic patients on haemodialysis. Nephrol Dial Transplant 15:851-855, 2000
565. Kimura H, Gejyo F, Suzuki S, Miyazaki R: The C677T methylenetetrahydrofolate reductase gene mutation in hemodialysis patients. J Am Soc Nephrol 11:885-893, 2000
566. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW: Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 34:669-677, 1999
567. Clarke R, Armitage J: Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 26:341-348, 2000
568. van Guldener C, Stehouwer CD: Homocysteine-lowering treatment: an overview. Expert Opin Pharmacother 2:1449-1460, 2001
569. Molloy AM, Scott JM: Folates and prevention of disease. Public Health Nutr 4:601-609, 2001
570. Pietrzik K: Rationale for risk reduction of cardiovascular disease using homocysteine concentration in blood and plasma as biomarker: support by clinical data. Bibl Nutr Dieta :34-41, 2001
571. Biasioli S, Schiavon R: Homocysteine as a cardiovascular risk factor. Blood Purif 18:177-182, 2000
572. Morris ST, Jardine AG: The vascular endothelium in chronic renal failure. J Nephrol 13:96-105, 2000
573. Descombes E, Boulat O, Bersier LF, Fellay G: Difference in the homocysteine-lowering effect of folic acid in haemodialysis patients with and without occlusive vascular disease. Nephrol Dial Transplant 16:585-589, 2001
574. Naruszewicz M, Klinke M, Dziewanowski K, Staniewicz A, Bukowska H: Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin. Metabolism 50:131-134, 2001
575. Stanford JL, Molina H, Phillips J, Kohlman-Trigoboff D, Moore J, Smith BM: Oral folate reduces plasma homocyst(e)ine levels in hemodialysis patients with cardiovascular disease. Cardiovasc Surg 8:567-571, 2000
576. McGregor D, Shand B, Lynn K: A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease. Nephron 85:215-220, 2000
577. Spence JD, Cordy P, Kortas C, Freeman D: Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol 19:405-410, 1999
578. Hong SY, Yang DH, Chang SK: Plasma homocysteine, vitamin B6, vitamin B12 and folic acid in end-stage renal disease during low-dose supplementation with folic acid. Am J Nephrol 18:367-372, 1998
579. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 123:193-202, 1996
580. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49:147-152, 1996
581. Bostom AG, Shemin D, Yoburn D, Fisher DH, Nadeau MR, Selhub J: Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 120:241-244, 1996
582. Bostom AG, Shemin D, Nadeau MR, Shih V, Stabler SP, Allen RH, Selhub J: Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 113:129-132, 1995
583. Skoupy S, Fodinger M, Veitl M, Perschl A, Puttinger H, Rohrer C, Schindler K, Vychytil A, Horl WH, Sunder-Plassmann G: Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol 13:1331-1337, 2002
584. Harpel PC, Gordon BR, Parker TS: Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci U S A 86:3847-3851, 1989
585. Utermann G: Lipoprotein(a), in The Metabolic & Molecular Bases of Inherited Disease, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, 2000, pp 2753-2787
586. Dieplinger H, Kronenberg F: Genetics and metabolism of lipoprotein(a) and their clinical implications (Part 1). Wien Klin Wochenschr 111:5-20, 1999
587. Dieplinger H, Kronenberg F: Genetics and metabolism of lipoprotein(a) and clinical implications (Part 2). Wien Klin Wochenschr 111:46-55, 1999
588. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE: Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 44:2301-2306, 1998
589. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085, 2000
590. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, Von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11:105-115, 2000
591. Sechi LA, Zingaro L, De Carli S, Sechi G, Catena C, Falleti E, Dell’Anna E, Bartoli E: Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 129:457-461, 1998
592. Dieplinger H, Lackner C, Kronenberg F, Sandholzer C, Lhotta K, Hoppichler F, Graf H, Konig P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91:397-401, 1993
593. Parsons DS, Reaveley DA, Pavitt DV, Brown EA: Relationship of renal function to homocysteine and lipoprotein(a) levels: the frequency of the combination of both risk factors in chronic renal impairment. Am J Kidney Dis 40:916-923, 2002
594. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
595. Milionis HJ, Elisaf MS, Tselepis A, Bairaktari E, Karabina SA, Siamopoulos KC: Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure. Am J Kidney Dis 33:1100-1106, 1999
596. Wanner C, Rader D, Bartens W, Kramer J, Brewer HB, Schollmeyer P, Wieland H: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119:263-269, 1993
597. Kronenberg F, Lingenhel A, Lhotta K, Rantner B, Kronenberg MF, Konig P, Thiery J, Koch M, von Eckardstein A, Dieplinger H: The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int 65:606-612, 2004
598. Kronenberg F, Konig P, Lhotta K, Ofner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 14:1399-1404, 1994
599. Kronenberg F, Lhotta K, Konig P, Margreiter R, Dieplinger H, Utermann G: Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. Eur J Hum Genet 11:693-699, 2003
600. Kerschdorfer L, Konig P, Neyer U, Bosmuller C, Lhotta K, Auinger M, Hohenegger M, Riegler P, Margreiter R, Utermann G, Dieplinger H, Kronenberg F: Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up. Atherosclerosis 144:381-391, 1999
601. Stenvinkel P, Heimburger O, Tuck CH, Berglund L: Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 53:1336-1342, 1998
602. Kang DH, Yoon KI, Lee SW, Kang SW, Choi KH, Lee HY, Han DS: Impact of nutritional status on serum lipoprotein (a) concentration in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 16:S241-245, 1996 (suppl 1)
603. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10:1027-1036, 1999
604. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, Kronenberg F: Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8:1889-1898, 1997
605. Longenecker JC, Klag MJ, Marcovina SM, Powe NR, Fink NE, Giaculli F, Coresh J, ESRD TCfHOiCf: Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation 106:2812-2818, 2002
606. Longenecker JC, Coresh J, Marcovina SM, Powe NR, Levey AS, Giaculli F, Fink NE, Klag MJ: Lipoprotein(a) and prevalent cardiovascular disease in a dialysis population; The Choices for Healthy Outcome in Caring for ESRD (Choice) Study. Am J Kidney Dis 42:108-116, 2003
607. Ohkuma T, Minagawa T, Takada N, Ohno M, Oda H, Ohashi H: C-reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am J Kidney Dis 42:355-361, 2003
608. Koda Y, Nishi S, Suzuki M, Hirasawa Y: Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 56:S251-S253, 1999
609. Ohashi H, Oda H, Ohno M, Watanabe S, Sakata S: Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int Suppl 71:S242-244, 1999
610. Cressman MD, Heyka RJ, Paganini EP, O’Neil J, Skibinski CI, Hoff HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
611. Geroldi D, Bellotti V, Buscaglia P, Bonetti G, Gazzaruso C, Caprioli A, Fratino P: Characterization of apo(a) polymorphism by a modified immunoblotting technique in an Italian population sample. Clin Chim Acta 221:159-169, 1993
612. Koch M, Gradaus F, Schoebel FC, Leschke M, Grabensee B: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dial Transplant 12:1187-1191, 1997
613. Iliescu EA, Marcovina SM, Morton AR, Lam M, Koschinsky ML: Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dialysis Int 22:492-499, 2002
614. Guz G, Nurhan Ozdemir F, Sezer S, Isiklar I, Arat Z, Turan M, Haberal M: Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. Am J Kidney Dis 36:826-836, 2000
615. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9:1277-1284, 1998
616. Avram MM, Sreedhara R, Patel N, Chattopadhyay J, Thu T, Fein P: Is an elevated level of serum lipoprotein (a) a risk factor for cardiovascular disease in CAPD patients? Adv Perit Dial 12:266-271, 1996
617. Webb AT, Reaveley DA, O’Donnell M, O’Connor B, Seed M, Brown EA: Lipids and lipoprotein(a) as risk factors for vascular disease in patients on renal replacement therapy. Nephrol Dial Transplant 10:354-357, 1995
618. Kronenberg F, Kathrein H, Konig P, Neyer U, Sturm W, Lhotta K, Grochenig E, Utermann G, Dieplinger H: Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterioscler Thromb 14:1405-1411, 1994
619. Gazzaruso C, Bonetti G, Garzaniti A, Pini G, Ragazzoni A, Bianchi C, Jucci A, Buscaglia P, Geroldi D: Increased plasma concentrations of lipoprotein(a) for every phenotype of apolipoprotein(a) in patients with chronic renal failure treated by hemodialysis. Nutr Metab Cardiovasc Dis 6:203-210, 1996
620. Kimura K, Saika Y, Otani H, Fujii R, Mune M, Yukawa S: Factors associated with calcification of the abdominal aorta in hemodialysis patients. Kidney Int Suppl 71:S238-S241, 1999
621. Koch M, Kutkuhn B, Grabensee B, Ritz E: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 12:2603-2611, 1997
622. Gault MH, Longerich LL, Purchase L, Harnett J, Breckenridge C: Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature. Nephron 70:155-170, 1995
623. Lye WC, Hughes K, Leong SO, Lee EJ: Lipoprotein (a) levels and clinical correlations in CAPD patients. Adv Perit Dial 11:131-133, 1995
624. Auguet T, Senti M, Rubies-Prat J, Pelegri A, Pedro-Botet J, Nogues X, Romero R: Serum lipoprotein(a) concentration in patients with chronic renal failure receiving haemodialysis: influence of apolipoprotein (a) genetic polymorphism. Nephrol Dial Transplant 8:1099-1103, 1993
625. Petersen LJ, Ringsdal VS, Ladefoged SD, Baslund B, Hansen PR: Anticardiolipin antibodies and lipoprotein (a) levels in patients with chronic renal failure treated with dialysis: associations with atherothrombotic disease. Int J Artif Organs 19:339-342, 1996
626. Bostom AG, Shemin D, Lapane KL, Sutherland P, Nadeau MR, Wilson PW, Yoburn D, Bausserman L, Tofler G, Jacques PF, Selhub J, Rosenberg IH: Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis 125:91-101, 1996
627. Webb AT, Brown EA: Prevalence of symptomatic arterial disease and risk factors for its development in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 13:S406-408, 1993 (suppl 2)
628. Olmer M, Renucci JE, Planells R, Bouchouareb D, Purgus R: Preliminary evidence for a role of apolipoprotein E alleles in identifying haemodialysis patients at high vascular risk. Nephrol Dial Transplant 12:691-693, 1997
629. Docci D, Manzoni G, Bilancioni R, Delvecchio C, Capponcini C, Baldrati L, Neri L, Feletti C: Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis. Int J Artif Organs 17:41-45, 1994
630. Wanner C, Bartens W, Walz G, Nauck M, Schollmeyer P: Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients. Nephrol Dial Transplant 10:75-81, 1995
631. Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S: Role of lipoprotein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J Am Soc Nephrol 11:1889-1895, 2000
632. Parsy D, Dracon M, Cachera C, Parra HJ, Vanhoutte G, Tacquet A, Fruchart JC: Lipoprotein abnormalities in chronic haemodialysis patients. Nephrol Dial Transplant 3:51-56, 1988
633. Goldwasser P, Michel MA, Collier J, Mittman N, Fein PA, Gusik SA, Avram MM: Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. Am J Kidney Dis 22:215-225, 1993
634. Kronenberg F: Lipoprotein(a) in renal disease: what we have, what we need, what we can forget. Nephrol Dial Transplant 10:766-769, 1995
635. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 7:198-207, 1996
636. Kopple JD, Greene T, Chumlea WC, Hollinger D, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang SR, Zimmer GS: Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. Kidney Int 57:1688-1703, 2000
637. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filho JC, Gutierrez A, Lindholm B, Bergstrom J: Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 53:773-782, 1998
638. Jansen MA, Korevaar JC, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT: Renal function and nutritional status at the start of chronic dialysis treatment. J Am Soc Nephrol 12:157-163, 2001
639. Avram MM, Fein PA, Bonomini L, Mittman N, Loutoby R, Avram DK, Chattopadhyay J: Predictors of survival in continuous ambulatory peritoneal dialysis patients: a five-year prospective study. Perit Dial Int 16:S190-194, 1996 (suppl 1)
640. Ikizler TA, Greene JH, Wingard RL, Parker RA, Hakim RM: Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 6:1386-1391, 1995
641. Chazot C, Laurent G, Charra B, Blanc C, VoVan C, Jean G, Vanel T, Terrat JC, Ruffet M: Malnutrition in long-term haemodialysis survivors. Nephrol Dial Transplant 16:61-69, 2001
642. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple JD: Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 80:299-307, 2004
643. Sezer S, Ozdemir FN, Arat Z, Turan M, Haberal M: Triad of malnutrition, inflammation, and atherosclerosis in hemodialysis patients. Nephron 91:456-462, 2002
644. Kaizu Y, Ohkawa S, Odamaki M, Ikegaya N, Hibi I, Miyaji K, Kumagai H: Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 42:295-302, 2003
645. Keane WF, Collins AJ: Influence of co-morbidity on mortality and morbidity in patients treated with hemodialysis. Am J Kidney Dis 24:1010-1018, 1994
646. Beddhu S, Pappas LM, Ramkumar N, Samore MH: Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol 15:733-742, 2004
647. Higashi Y, Sasaki S, Nakagawa K, Kimura M, Noma K, Hara K, Matsuura H, Goto C, Oshima T, Chayama K, Yoshizumi M: Low body mass index is a risk factor for impaired endothelium-dependent vasodilation in humans: role of nitric oxide and oxidative stress. J Am Coll Cardiol 42:256-263, 2003
648. Goldstein DJ: Renal disease, in Essential of Nutrition and Diet Therapy, edited by Rodewell, Williams K, Schenker E, 2003, pp 519-548
649. Owen WF, Jr., Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
650. Beddhu S, Kaysen GA, Yan G, Sarnak M, Agodoa L, Ornt D, Cheung AK: Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis 40:721-727, 2002
651. Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW: Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 60:333-340, 2001
652. Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl:103-108, 2002
653. Dutton J, Campbell H, Tanner J, Richards N: Pre-dialysis serum albumin is a poor indicator of nutritional status in stable chronic haemodialysis patients. Edtna Erca J 25:36-37, 1999
654. Struijk DG, Krediet RT, Koomen GC, Boeschoten EW, Arisz L: The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival. Perit Dial Int 14:121-126, 1994
655. Kaysen GA: Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 9:2368-2376, 1998
656. Sousa MM, Norden AG, Jacobsen C, Willnow TE, Christensen EI, Thakker RV, Verroust PJ, Moestrup SK, Saraiva MJ: Evidence for the role of megalin in renal uptake of transthyretin. J Biol Chem 275:38176-38181, 2000
657. Chertow GM, Ackert K, Lew NL, Lazarus JM, Lowrie EG: Prealbumin is as important as albumin in the nutritional assessment of hemodialysis patients. Kidney Int 58:2512-2517, 2000
658. Panzetta G, Tessitore N, Faccini G, Maschio G: The protein catabolic rate as a measure of protein intake in dialysis patients: usefulness and limits. Nephrol Dial Transplant 5:125-127, 1990 (suppl 1)
659. Kerr PG, Strauss BJ, Atkins RC: Assessment of the nutritional state of dialysis patients. Blood Purif 14:382-387, 1996
660. Jones CH, Akbani H, Croft DC, Worth DP: The relationship between serum albumin and hydration status in hemodialysis patients. J Ren Nutr 12:209-212, 2002
661. Dumler F, Kilates C: Use of bioelectrical impedance techniques for monitoring nutritional status in patients on maintenance dialysis. J Ren Nutr 10:116-124, 2000
662. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 55:1945-1951, 1999
663. Heimburger O, Qureshi AR, Blaner WS, Berglund L, Stenvinkel P: Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis 36:1213-1225, 2000
664. Baker JP, Detsky AS, Wesson DE, Wolman SL, Stewart S, Whitewell J, Langer B, Jeejeebhoy KN: Nutritional assessment: a comparison of clinical judgement and objective measurements. N Engl J Med 306:969-972, 1982
665. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, Jeejeebhoy KN: What is subjective global assessment of nutritional status? J Parenter Enteral Nutr 11:8-13, 1987
666. Cooper BA, Bartlett LH, Aslani A, Allen BJ, Ibels LS, Pollock CA: Validity of subjective global assessment as a nutritional marker in end-stage renal disease. Am J Kidney Dis 40:126-132, 2002
667. Wang AY, Woo J, Wang M, Sea MM, Ip R, Li PK, Lui SF, Sanderson JE: Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 12:1927-1936, 2001
668. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW: Body mass index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 16:2386-2394, 2001
669. Leavey SF, Strawderman RL, Jones CA, Port FK, Held PJ: Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am J Kidney Dis 31:997-1006, 1998
670. Fleischmann E, Teal N, Dudley J, May W, Bower JD, Salahudeen AK: Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients [erratum appears in Kidney Int 2000 Feb;57(2):760]. Kidney Int 55:1560-1567, 1999
671. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA: Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13:1061-1066, 2002
672. Lowrie EG, Li Z, Ofsthun N, Lazarus JM: Body size, dialysis dose and death risk relationships among hemodialysis patients. Kidney Int 62:1891-1897, 2002
673. Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C: Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study. Nephron 31:103-110, 1982
674. Iseki K, Yamazato M, Tozawa M, Takishita S: Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 61:1887-1893, 2002
675. Fleischmann EH, Bower JD, Salahudeen AK: Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J 47:74-81, 2001
676. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, Heimburger O, Lindholm B, Bergstrom J: Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 57:1727-1735, 2000
677. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 15:442-453, 2004
678. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63:793-808, 2003
679. Kalantar-Zadeh K, Fouque D, Kopple JD: Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr 14:64-71, 2004
680. Ooi DS, Zimmerman D, Graham J, Wells GA: Cardiac troponin T predicts long-term outcomes in hemodialysis patients. Clin Chem 47:412-417, 2001
681. Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J, Hopkins PN: Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 87:129-135, 2001
682. Jorde LB, Williams RR: Relation between family history of coronary artery disease and coronary risk variables. Am J Cardiol 62:708-713, 1988
683. Hopkins PN, Williams RR, Kuida H, Stults BM, Hunt SC, Barlow GK, Ash KO: Family history as an independent risk factor for incident coronary artery disease in a high-risk cohort in Utah. Am J Cardiol 62:703-707, 1988
684. Liao D, Myers R, Hunt S, Shahar E, Paton C, Burke G, Province M, Heiss G: Familial history of stroke and stroke risk. The Family Heart Study. Stroke 28:1908-1912, 1997
685. Myers RH, Kiely DK, Cupples LA, Kannel WB: Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J 120:963-969, 1990
686. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015-2022, 2002
687. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113, 1995
688. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L: Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 98:2520-2526, 1998
689. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9, 1996
690. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG: MTHFR 677C–>T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288:2023-2031, 2002
691. Morimoto K, Haneda T, Okamoto K, Ishida H, Kikuchi K: Methylenetetrahydrofolate reductase gene polymorphism, hyperhomocysteinemia, and cardiovascular diseases in chronic hemodialysis patients. Nephron 90:43-50, 2002
692. Lim PS, Hung WR, Wei YH: Polymorphism in methylenetetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis. Nephron 87:249-256, 2001
693. Haviv YS, Shpichinetsky V, Goldschmidt N, Abou A, I, Ben Yehuda A, Friedman G: The Common Mutations C677T and A1298C in the Human Methylenetetrahydrofolate Reductase Gene Are Associated with Hyperhomocysteinemia and Cardiovascular Disease in Hemodialysis Patients. Nephron 92(1):120-6, 2002
694. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP: Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15:420-426, 2004
695. Sing CF, Davignon J: Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 37:268-285, 1985
696. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csazar A, Utermann G: The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 49:338-349, 1991
697. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM: Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 16:1250-1255, 1996
698. Lim PS, Liu CS, Hong CJ, Wei YH: Prevalence of apolipoprotein E genotypes in ischaemic cerebrovascular disease in end-stage renal disease patients. Nephrol Dial Transplant 12:1916-1920, 1997
699. Imura T, Kimura H, Gejyo F: Apolipoprotein E phenotypes in hemodialysis patients. Kidney Int Suppl 71:S245-S247, 1999
700. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop M, Peto R, Collins R: Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 355:434-442, 2000
701. Aucella F, Margaglione M, Vigilante M, Gatta G, Grandone E, Forcella M, Ktena M, De Min A, Salatino G, Procaccini D, Stallone C: PAI-1 4G/5G and ACE I/D gene polymorphisms and the occurrence of myocardial infarction in patients on intermittent dialysis. Nephrol Dial Transplant 18:1142-1146, 2003
702. Losito A, Kalidas K, Santoni S, Ceccarelli L, Jeffery S: Polymorphism of renin-angiotensin system genes in dialysis patients-association with cerebrovascular disease. Nephrol Dial Transplant 17(12):2184-2188, 2002
703. Schmidt A, Kiener HP, Barnas U, Arias I, Illievich A, Auinger M, Graninger W, Kaider A, Mayer G: Angiotensin-converting enzyme polymorphism in patients with terminal renal failure. J Am Soc Nephrol 7:314-317, 1996
704. Nergizoglu G, Keven K, Gurses MA, Aras O, Erturk S, Duman N, Ates K, Akar H, Akar N, Karatan O, Erbay B, Ertug AE: Carotid intima-media thickness and ACE-gene polymorphism in hemodialysis patients. J Nephrol 12:261-265, 1999
705. Aucella F, Vigilante M, Margaglione M, Grandone E, del Popolo A, Forcella M, Procaccini D, Salatino G, Passione A, Ktena M, De Min A, Stallone C: Polymorphism of the angiotensin-converting enzyme gene in end-stage renal failure patients. Nephron 85:54-59, 2000
706. Higashiuesato Y, Tana T, Tozawa M, Iseki C, Iseki K, Fukiyama K, Takishita S: Angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and survival in a cohort of chronic hemodialysis patients. Clin Nephrol 58:370-375, 2003
707. Osono E, Kurihara S, Hayama N, Sakurai Y, Ohwada K, Onoda N, Takeuchi M, Tomizawa T, Komaba Y, Hashimoto K, Matsunobu S, Yoneshima H, Iino Y: Insertion/deletion polymorphism in intron 16 of the ACE gene and left ventricular hypertrophy in patients with end-stage renal disease. Am J Kidney Dis 32:725-730, 1998
708. Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR: Interleukin-10. Annu Rev Immunol 11:165-190, 1993
709. Girndt M, Kaul H, Sester U, Ulrich C, Sester M, Georg T, hler H: Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 62:949-955, 2002
710. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV: An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1-8, 1997
711. Pecoits-Filho R, Stenvinkel P, Marchlewska A, Heimburger O, Barany P, Hoff CM, Holmes CJ, Suliman M, Lindholm B, Schalling M, Nordfors L: A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl:S172-176, 2003
712. Lim VS: Reproductive function in patients with renal insufficiency. Am J Kidney Dis 9:363-367, 1987
713. Lim VS, Henriquez C, Sievertsen G, Frohman LA: Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med 93:21-27, 1980
714. Zingraff J, Jungers P, Pelissier C, Nahoul K, Feinstein MC, Scholler R: Pituitary and ovarian dysfunctions in women on haemodialysis. Nephron 30:149-153, 1982
715. Gomez F, de la Cueva R, Wauters JP, Lemarchand-Beraud T: Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin. Am J Med 68:522-530, 1980
716. Holley JL, Schmidt RJ, Bender FH, Dumler F, Schiff M: Gynecologic and reproductive issues in women on dialysis. Am J Kidney Dis 29:685-690, 1997
717. Stehman-Breen CO, Gillen D, Gipson D: Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney Int 56:2243-2247, 1999
718. Ginsburg ES, Walsh B, Greenberg L, Price D, Chertow GM, Owen WF, Jr.: Effects of estrogen replacement therapy on the lipoprotein profile in postmenopausal women with ESRD. Kidney Int 54:1344-1350, 1998
719. Pines A, Fisman EZ, Ayalon D, Drory Y, Averbuch M, Levo Y: Long-term effects of hormone replacement therapy on Doppler-derived parameters of aortic flow in postmenopausal women. Chest 102:1496-1498, 1992
720. McCrohon JA, Adams MR, McCredie RJ, Robinson J, Pike A, Abbey M, Keech AC, Celermajer DS: Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin Endocrinol (Oxf) 45:435-441, 1996
721. Gangar KF, Reid BA, Crook D, Hillard TC, Whitehead MI: Oestrogens and atherosclerotic vascular disease–local vascular factors. Baillieres Clin Endocrinol Metab 7:47-59, 1993
722. Akkad A, Hartshorne T, Bell PR, al-Azzawi F: Carotid plaque regression on oestrogen replacement: a pilot study. Eur J Vasc Endovasc Surg 11:347-348, 1996
723. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV: Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 272:H1996-2003, 1997
724. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321-333, 2002
725. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 273:199-208, 1995
726. Ginsburg ES, Owen WF, Jr., Greenberg LM, Shea BF, Lazarus JM, Walsh BW: Estrogen absorption and metabolism in postmenopausal women with end-stage renal disease. J Clin Endocr Metab 81:4414-4417, 1996
727. van Kammen E, Thijssen JH, Donker GH, Schwarz F: The excretion of metabolites of testosterone and of estradiol in male patients with chronic renal failure. Steroids 26:508-515, 1975
728. Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. Menopause 10:6-12, 2003
729. O’Hare AM, Feinglass J, Reiber GE, Rodriguez RA, Daley J, Khuri S, Henderson WG, Johansen KL: Postoperative mortality after nontraumatic lower extremity amputation in patients with renal insufficiency. J Am Soc Nephrol 15:427-434, 2004
730. Standards of medical care for patients with diabetes mellitus. Diabetes Care 25:213-229, 2002
731. Rith-Najarian S, Branchaud C, Beaulieu O, Gohdes D, Simonson G, Mazze R: Reducing lower-extremity amputations due to diabetes. Application of the staged diabetes management approach in a primary care setting. J Fam Pract 47:127-132, 1998
732. Litzelman DK, Slemenda CW, Langefeld CD, Hays LM, Welch MA, Bild DE, Ford ES, Vinicor F: Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial. Ann Intern Med 119:36-41, 1993
733. McMurray SD, Johnson G, Davis S, McDougall K: Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 40:566-575, 2002
734. Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC: Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 62:1799-1805, 2002
735. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42:201-208, 2003
736. Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO: Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 64:1455-1461, 2003